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Living Sweet: A Multi-Functional Mobile-Phone Application Strategy for Adults with 
Uncontrolled Type 2 Diabetes Mellitus  
Chantel Anderson DNP, APRN, FNP-BC 
Type 2 Diabetes Mellitus (T2DM), one of the most common chronic diseases, is increasing 
worldwide, and once diagnosed, lifetime self-management is critical to maintain glycemic control 
(Vermeire et al., 2005; American Diabetes Association (ADA), 2018). Management of T2DM has 
been acknowledged as challenging due to the need for strict lifestyle adaptations. From a public 
health perspective, uncontrolled diabetes leads to increased healthcare costs, secondary 
complications, and ultimately severe disabilities (ADA, 2018). The purpose of this evidence-
based practice (EBP) project was to evaluate the effectiveness of a diabetes-specific mobile 
health application (MHA) on glycated-hemoglobin (HbA1C),  self-care perception (SCP), and 
self-care behaviors (SCB). The Iowa model was used to guide this project in primary care 
settings in Northwest Indiana. A retrospective chart review determined that a high number 
adults had uncontrolled T2DM. A protocol was developed and implemented over an 8-week 
period. A within group design was used for pre and post-intervention evaluation of the HbA1C 
and SCP using paired-samples t tests. Statistically significant differences were noted in pre-
HbA1C (M = 9.95; SD = 1.07) compared to post-HbA1C (M = 8.21; SD = 1.10) (t = 6.674, df = 
17, *p < 0.05), and in pre-SCP (M = 34.6; SD = 10.5) compared to post-SCP (M = 42.6; SD = 
8.09) (t = -4.403, df = 17, *p < 0.05). A statistically significant difference in project-specific pre- 
and post- intervention SCBs were found with the behaviors of checking glucose (Z = 2.389, *p < 
.05), recording glucose (Z = 2.666, *p < .05), and medication adherence (Z = 2.313, *p < .05). 
There was not a statistically significant difference in the perception of activity engagement (Z = 
1.718, p > .05). Results indicated that a MHA intervention had a statistically and clinically 
significant impact on HbA1C, SCP, and SCBs with the exception of activity engagement.
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CHAPTER 1 
INTRODUCTION 
Despite being the most expensive healthcare system among developed countries, the 
U.S. ranks the lowest in key health outcomes and in many aspects of access to care (Bondurant 
& Armstrong, 2016). Additionally, changes in reimbursement structure and challenges related to 
both quality and healthcare cost beg for a healthcare reform. Health care payment methods are 
changing from fee-for-service to value-based systems where payment is based on clinical 
quality outcomes and cost containment (Greenwood, Gee, Fatkin, & Peeples, 2017). From a 
public health perspective, uncontrolled diabetes leads to increased healthcare costs, secondary 
complications, and ultimately severe disabilities (ADA, 2018).  
Chronic disease management has been acknowledged as challenging due to the need 
for strict lifestyle adaptations (Vermeire et al., 2005). Type 2 Diabetes Mellitus (T2DM), one of 
the most common chronic diseases, is increasing worldwide, and once diagnosed, lifetime self-
management is critical to maintain glycemic control. Glycemic control is defined as achieving a 
HbA1C level that ranges from 6.0 % to 7.0 %, or blood glucose averages of 126 mg/dl to 152 
mg/dl respectively, which has direct correlation with long-term prognosis for patients with T2DM 
(ADA, 2018). Glycemic control for diabetics who have experienced blood sugars less than 60 
are expected to achieve less stringent HbA1C levels of < 8.0% (ADA, 2018). HbA1C 
measurement signifies the average blood sugar over a 8 to 12-week timeframe. Research has 
indicated that adherence to traditional interventions for the treatment of diabetes mellitus is 
poor, and as a result there has been little improvement of glycemic control (Vermeire et al., 
2005).  
The aim of managing T2DM is to attain glycemic control (ADA, 2018). Self-care 
behaviors and lifestyle modifications are aimed at overall reduction of HbA1C levels and are 
mainstays in the treatment and management of Diabetes Mellitus (DM) (ADA, 2018). Thus, the 
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diffusion into practice of the best evidence for the self-management of diabetes is essential as 
the management of chronic disease becomes a focus throughout health organizations. 
Uncontrolled diabetes and chronic hyperglycemia are also associated with increased risk for 
cardiovascular disease, retinopathy, nephropathy, neuropathy (ADA, 2018; Vermeire et al., 
2005), as well as increased mortality for those who suffer with this unforgiving disease (Wu et 
al., 2017).  
Through an extensive literature search, evidence indicated that the use of mobile health 
applications (MHAs) was found to be the best practice for the encouragement of self-care 
practices for the management of adults with T2DM and found to a significantly reduce HbA1C 
levels (Alharbi et al., 2016; Bonoto et al., 2017; Clement et al., 2018; Cui, Wu, Mao, Wang, & 
Nie, 2016; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Pal et al., 2014; Wang, Xue, Huang, 
Huang, & Zhang, 2017; Whitehead & Seaton, 2016; Wu, Guo, & Zhang, 2019; Wu et al., 2017; 
Yoshida et al., 2018). In 2014 64 % of Americans were using smartphone technology. Research 
indicates that using a diabetes MHA through a smartphone can increase adherence to diabetes 
management and self-care efforts (Fu et al., 2017). MHA technology provides a platform for the 
rapid development of patient-centered care that supports the self-management of DM beyond 
traditional computer or web-based programs, and institution-based diabetes education 
programs (Greenwood, Gee, Fatkin, & Peeples, 2017). 
The purpose of this evidence-based practice (EBP) project is to evaluate the 
effectiveness of a diabetes-specific mobile health application (MHA) on HbA1C levels, self-care 
perception, and self-care behaviors. The clinical question being addressed is, what is the best 
practice for adult T2DM patients to achieve glycemic control and improve self-care behaviors. 
Additionally, the clinical question also addresses the impact of a MHA on self-care perception. 
This project was posed to identify what intervention has been found in the best evidence, to 
achieve glycemic control in adult T2DM patients, thereby lessening debilitating complications 
related to chronically elevated HbA1C levels.  
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Data from the Literature Supporting Need for the Project 
 Currently, 30.3 million people have DM in the U.S., this number includes an alarming 
estimation of 7.2 million who have gone undiagnosed (ADA, 2018; CDC, 2017). T2DM affects 
382 million globally, and the incidence of this disease is expected to increase to 500 million by 
2030 (ADA, 2018; CDC, 2017;  Fu, McMahon, Gross, Adam, & Wyman, 2017; Hou, Carter, 
Hewitt, Francisa, & Mayor, 2016). The percentage of adults with diabetes increases with age; 
25.5% of those aged 65 and older have been diagnosed with this chronic disease (CDC, 2017). 
Of an estimated 1.5 million new cases diagnosed in 2015, more than half were aged 45-65 
years and equally distributed among men and women (CDC, 2017). Coexisting conditions and 
complications secondary to uncontrolled diabetes include cardiovascular disease, stroke, 
diabetic ketoacidosis, kidney disease. eye disease, and amputation of a lower extremity (CDC, 
2017). In the U.S., major cardiovascular diseases were found in 1.5 million diabetics which 
included 400,000 with ischemic heart disease, and 251,000 stroke events. Amputations of the 
lower extremities as a result of uncontrolled diabetes occurred 11.5 per 1,000 persons with 
diabetes (CDC, 2017). In 2015, other uncontrolled diabetes-related events led to 14.2 million 
emergency department visits from hypoglycemia (very low blood sugar) and hyperglycemia 
(very high blood sugar) (CDC, 2017). This chronic disease was the seventh leading cause of 
death in the U.S. in 2015, and had an estimated cost of $245 billion (CDC, 2017). Economic 
costs of untreated and uncontrolled DM increased 26% from 2012 to 2017 (ADA, 2018; Fu et 
al., 2017). Poor self-management practice lead to uncontrolled HbA1C levels (greater than 8.0), 
and have led to significant financial burden to the individual and to society (ADA, 2018). The 
ongoing responsibility of administering medication, testing blood glucose levels, and adhering to 
lifestyle modifications can be quite overwhelming, furthermore, patients often do not typically 
document self-management behaviors. From a clinical experience perspective, the lack of 
documentation creates a significant challenge for health care providers to identify the problem 
and adjust therapy to meet the needs of the individual.  
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Data from the Clinical Agency Supporting Need for the Project 
 This project is a pilot program that will be implemented in primary health care settings 
within the guidelines of certified rural health centers. These clinical sites are located in rural 
Indiana, are family practice focused, and have a medical group consisting of physicians and 
nurse practitioners. The four facilities are located in small rural towns in northwest Indiana. The 
clientele is generally one of lower socio-economic status with the main payor source received 
from Medicare and Medicaid Services. After an electronic medical record (EMR) query, it was 
found that well over 200 patients on service had either type I diabetes mellitus (T1DM) or T2DM 
(Melissa Jones, Personal Communication, May 23, 2019). Organizational data, obtained 
through personal communication with the project preceptor, indicated poor outcome measures 
in 2019 quarter-one and quarter-two for HbA1C measurements of patients with diabetes 
mellitus. Centers for Medicare and Medicaid Services (CMS) specifically evaluate HbA1C levels 
of greater than 9.0 as the quality outcome measure for health care organizations (CMS, 2017). 
However, for the purpose of this project the ADA recommendation of HbA1C of 8.0 will be the 
used for evaluation purposes (ADA, 2018). Quarter-one indicated that 59.3% of diabetics within 
the primary care organization had HbA1C results of greater than 9.0, while quarter-two indicated 
that 66% had HbA1C greater than 9.0. These are considered poor quality measure outcomes 
and are well above the expected national standard of 45% (CMS, 2017). These poor-quality 
outcome results were the impetus for this EBP project. As a primary healthcare organization, it 
is the duty of those rendering care to seek out the best evidence and improve quality and safety 
of the receiving population. Within the practice in which the DNP student works, HbA1C levels 
above 9.0 % were at an all-time high of 59% for the second quarter in 2019. The 59% was less 
than the overall primary care group’s results of 66% of DM patients that had HbA1C of greater 
than 9.0%, but levels were still outside of the national standard (CMS, 2017).  
The DNP student manages 40 adults with T2DM, and has over 10 years’ experience 
treating and managing patients with this chronic disease. She has found it difficult to incite self-
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care behavior practices that positively impact HgA1C levels. Through an extensive search of the 
literature, evidence was found to support an intervention to improve the self-management of 
adults with T2DM.  
Purpose of the Evidence-Based Practice Project  
The purpose of this EBP project is to evaluate the effectiveness of using a diabetes- 
specific MHA, with associated individualized preference settings, as an 8-week intervention for 
adult T2DM patients with HbA1C levels above 8.0 in a primary healthcare setting. There is a 
large body of evidence that supports the use of diabetes-specific mobile health smartphone 
applications to significantly reduce HbA1C in this population. Essentially, this EBP project will 
include an intervention designed to foster behavioral changes that promote improved HbA1C 
results, diabetes self-management habits such as; medication compliance, blood sugar 
monitoring efforts, and physical activity engagement, and improve self-care perception. 
Evaluation will include determining if it significantly improved HbA1C results, self-care behaviors 
of blood glucose monitoring, physical activity engagement, medication adherence, and self-care 
perceptions for adult T2DM patients in a primary healthcare setting.  
Living Sweet 
The name of the new diabetes-specific MHA program was created through a competition 
held by the DNP student project leader. The competition was conducted through an email 
request not only to name the program, but also to entice staff engagement and interest. This 
approach was aligned with a transformational leadership model to motivate, inspire, and solicit 
buy-in of staff members who may be impacted by practice change (Brewer et al., 2016). The 
winning name of the competition, Living Sweet, was chosen by the mother of the DNP student 
project leader. Staff are key stakeholders and it is important for their participation in the adoption 
of new practice standards and for overall program success (Walston, 2017). 
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PICOT Question 
   In adult T2DM patients with HbA1C values higher than 8.0 in a primary healthcare 
setting (P) what is the effect of a diabetes-specific multi-functional mobile-phone application (I) 
compared to traditional diabetes education (C) on HbA1C results, self-care behaviors, and self-
care perception (O), over an 8-week period (T)?  
Significance of the EBP Project 
According to Vermeire et al. (2005) irrespective of the type of chronic disease, 
adherence to treatment recommendations are poor despite known consequences. This EBP 
project is important because it is a proactive approach that encourages adult T2DM patients to 
increase self-care behaviors which are directly associated with a reduction in HbA1C values 
(Alharbi et al., 2016; Bonoto et al., 2017; Clement et al., 2018; Cui, Wu, Mao, Wang, & Nie, 
2016; Fu, McMahon, Gross, Adam, & Wyman, 2017; Hou, Carter, Hewitt, Francisa, & Mayor, 
2016; Pal et al., 2014; Wang, Xue, Huang, Huang, & Zhang, 2017; Whitehead & Seaton, 2016;  
Wu, Guo, & Zhang, 2019; Wu et al., 2017; Yoshida et al., 2018). Moreover, studies have shown 
use of MHAs have a positive impact on self-care perception and self-confidence that is essential 
for self-management of a chronic disease (Bonoto et al., 2017; Clement et al., 2018; Pal et al., 
2014; Wu, Guo, & Zhang, 2019). Improvements in HbA1C is directly linked to a reduction of 
debilitating diabetes complications, cost burden, and associated mortality rates (Alharbi et al., 
2016; Bonoto et al., 2017; Yoshida et al., 2018). The use of MHAs addresses the current clinical 
problem through a technological platform that has shown statistically significant improvements 
in HbA1C results and accompanying self-care behaviors (Alharbi et al., 2016; Bonoto et al., 
2017; Clement et al., 2018; Cui, Wu, Mao, Wang, & Nie, 2016; Fu, McMahon, Gross, Adam, & 
Wyman, 2017; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Pal et al., 2014; Wang, Xue, 
Huang, Huang, & Zhang, 2017; Whitehead & Seaton, 2016;  Wu, Guo, & Zhang, 2019; Wu et 
al., 2017; Yoshida et al., 2018). Additionally, use of this technology has been shown to be cost-
effective, readily available, and user friendly (Alharbi et al., 2016; Clement et al., 2018; Holtz & 
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Lauckner, 2012; Pamaiahgari, 2018). The ADA’s Standards of Medical Care in Diabetes (2019) 
recommendations indicate that improving care and promoting health in the diabetic population is 
a standard of practice included in their evidence-based recommendations. Additionally, the ADA 
concluded that diabetes-specific technology, when applied appropriately, can improve the lives 
and health of people with diabetes (ADA, 2019). 
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CHAPTER 2 
EBP MODEL AND REVIEW OF LITERATURE 
Overview of EBP Model 
  Evidence-based practice (EBP) involves the use of reliable, explicit and judicious 
evidence to make decisions about the care of individual patients combining the results of well-
designed research, clinical expertise, patient concerns and patient preferences (Titler et al., 
2001). The best evidence is used as a guide to practice decisions which ultimately leads to high 
quality standards, controlled costs, and optimal patient care outcomes (Schmidt & Brown, 
2019). Ingersoll (2000), defines EBP as, “the conscientious, explicit, and judicious use of theory-
derived, research-based information in making decisions about care delivery to individuals or 
groups of patients and in consideration of individual needs and preferences” (p. 152). 
 The Iowa model was originally developed and implemented at the University of Iowa 
Hospitals and Clinics. It was used as a framework that focused on organization and 
collaboration incorporating clinical practice and use of research (Titler et al., 2001). Since its 
inception this model has been used to guide project decisions while focusing on evidence to 
support best practice effort (Titler et al., 2001). Originally, it was developed in 1994 as a 
research utilization model, but has been updated to include more emphasis on EBP. Significant 
developments in the healthcare market and feedback from users was the impetus to revise the 
model. Revisions included: incorporating new terminology and feedback loops; address the 
dynamic changes within the health care market; and encourage the use of other forms of 
evidence such as expert opinion and case reports when primary research was not available to 
guide practice. The model was ultimately renamed to the Iowa Model of Evidence-Based 
Practice to Promote Quality Care (Titler et al., 2001). This updated model allows nurses to focus 
on knowledge and problem-focused triggers that promoted critical thought about clinical practice 
effectiveness and operational efficiency, leading nurses to seek scientific knowledge to fill the 
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clinical and operational gaps within a unit or throughout an organization (Titler et al., 2001). The 
Iowa Model of Evidence-Based Practice to Promote Quality Care consists of 7 steps to promote 
quality care in a systematic method that demonstrates how organizations change practice 
based on the most current evidence (Schmidt & Brown, 2019). Step I is the selection of a topic 
for an EBP project for which many factors need to be considered including assessment of the 
priority and magnitude of the problem, the application to the primary healthcare setting, the 
contribution to improving care, the current practice problem area, staff dedication to practice 
change, and multidisciplinary impact of the problem (Titler et al., 2001). Step II is the 
engagement of a team that will be responsible for the development, implementation, and 
evaluation of the project. The makeup of the team is driven by the chosen topic and include 
associated stakeholders (Titler, 2001). In this step the team will determine whether the problem 
at hand is a priority for the organization, department, or unit in which they work. Problems that 
have a higher volume or cost associated will likely have a higher priority from an organizational 
standpoint. During this step, organizational buy-in is crucial and knowing the prioritization of the 
problem will help focus team efforts when grooming key stakeholders (Titler et al., 2001). 
 Step III entails evidence retrieval. Brainstorming amongst the members should be held 
to identify available resources to guide the search for evidence (Titler et al., 2001). Once the 
priority has been determined, the team members will help develop, evaluate, and implement the 
EBP change. The team should include interested interdisciplinary stakeholders and leaders, 
which include those outside of nursing (Titler et al., 2001). Step IV is the process of gathering, 
critiquing and synthesizing pertinent research related to the desired practice change. This is a 
systematic process that exposes the best supportive evidence available which is then assessed 
and critiqued for level and quality (Titler et al., 2001). This ensures the overall body of evidence 
has strength and merit (Schmidt & Brown, 2019). One of the most important parts of this step is 
to formulate a good question using the PICOT method (Titler et al., 2001) that takes into 
account the population, intervention, comparison, outcome, and time frame (Melnyk & Fineout-
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Overholt, 2015). Step V is the development of a patient-centered evidence-based practice 
standard that is highly individualized. Once the literature is critiqued, team members develop a 
set of recommendations that guide the new practice (Titler et al., 2001). The type and strength 
of evidence used in practice needs to be clear and based on the consistency of replicated 
studies (Titler et al., 2001). The development of a patient-centered EBP standard becomes a to 
guide clinical practice, assessments, actions, and treatment as required, and will be based on 
the group decision, considering the relevance for practice, its feasibility, appropriateness, 
meaningfulness, and effectiveness for practice (Titler et al., 2001). Evidence-based practice is 
ideally a patient-centered approach and when implemented is highly individualized (Titler et al., 
2001). Practice that fails to consider individual preferences of the individual patient is not 
evidence-based. Evidence-based practice must take into account patient autonomy, choice, and 
allow personal preference to be expressed (Schmidt & Brown, 2019; Titler, 2001).  
 Step VI is the implementation of the EBP standard which begins with written policies, 
procedures, and guidelines. Policy development requires direct interaction between the team 
members, direct care providers, and organizational leaders to support the practice change 
(Titler et al., 2001). The evidence also needs to be disseminated with the focus on its strengths 
and perceived benefits. This can be achieved through various communication lines such as in-
service education and hands on demonstration of the new practice change. Social and 
organizational factors can affect implementation and there needs to be support and value 
placed on the integration of evidence into practice and the application of research findings 
(Schmidt & Brown, 2019). The expertise of nurse champions can support the overall 
implementation of EBP into an organization. Nurse champions represent an untapped vital 
resource to change practice in today's metric-driven culture (Scanlon & Woolforde, 2016). 
Empowerment and a multidisciplinary approach are a few of the key attributes that have 
propelled the success of the nurse champion. Moreover, they have the ability to close the gap 
between evidence and practice as well as increase staff engagement in the work setting 
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(Scanlon & Woolforde, 2016). In some cases organizations are not ready or willing to assimilate 
EBP. Elements of system readiness include tension for change, EBP system fit, assessment of 
implications, support and advocacy for the EBP, dedication of time and resources, and the 
capacity to evaluate the impact of the EBP during and following implementation. Moreover, 
leadership support is critical for supporting EBP, and is expressed by providing necessary 
resources, materials, and time (Titler, 2006).  
Step VII is the evaluation step which is essential to seeing the value and contribution of 
the evidence into practice. Baseline comparison data prior to project implementation is 
beneficial to show how the new evidence-based practice standard has contributed to patient 
care (Titler, 2001). Audits and feedback should be conducted throughout the implementation 
process. It is essential that organizational leadership provide support during this step as 
success is not likely without support. Project evaluation will certainly bring to light the EBP 
project’s impact, but the project’s value to the organization can only be assessed against an 
actual change occurring with the desired outcome. For any change to take place, barriers that 
could hinder its progress need to be identified and addressed preferably before and 
during project implementation (Schmidt & Brown, 2019). 
Application of EBP Model to DNP Project 
 The application of Step I of the Iowa model, which is the selection of a topic, consisted of 
the project leader identifying a problem-focused trigger which raised the question: Is this topic a 
priority for the organization? Consultation with the organization’s quality and compliance director 
and project preceptor led the team to investigate quality metrics that surrounded HbA1C 
measures throughout the primary care organization. An internal data search revealed the 
priority and magnitude of the current problem directly related to elevated HbA1C measures and 
uncontrolled T2DM. Current practice problems were assessed and care rendered was found to 
be outdated and lacking EBP standards. First-quarter quality measures of 2019 indicated that 
59% of diabetic patients within this primary healthcare organization in rural Indiana submitted 
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reports of HbA1C results of greater than 9%. Second-quarter quality measures reports for this 
same organization resulted in 66% of diabetic patients with HbA1C levels greater than 9%. 
These value translate into an average daily blood sugar of 215 mg/dl., and were the impetus for 
this EBP project. According to the ADA (2018) the goal HbA1C ranges from 6.0% - 7.0% or an 
average daily blood sugar of 115 mg/dl to 150mg/dl. However, there are multiple factors the 
dictate target HbA1C for those individuals with diabetes mellitus; for those with more severe 
disease, control of diabetes is to achieve a HbA1C of 8% is recommended (ADA, 2018).  
Step II, forming a team, consisted of the project leader selecting key team players for the 
development, implementation, and evaluation of the project. The team composition was 
determined based on the project topic and includes key stakeholders such as primary care 
providers, senior leadership, and a compliance and quality director. Initiation of this step 
includes a PowerPoint presentation that will educate key stakeholders about the new practice 
change. The presentation is designed to provide project  details and engender enthusiasm for 
the EBP project. This effort is to encourage buy-in from key stakeholders, as well as enhance 
recruitment of additional team members and champions within the organization.  
Step III, evidence retrieval, entails an exhaustive literature search and active 
brainstorming with team members to identify resources available to support the evidence search 
process. The exhaustive literature search involves gathering the most current and relevant 
evidence to support the best practice for the treatment of HbA1C that is greater than 8% and is 
considered to be uncontrolled.  
Step IV, grading the evidence, consisted of the project leader leveling and appraising 
evidence consistent with predetermined inclusion criteria. The focus is to get high-level and 
high-quality evidence to determine what the best practice should include and to support the 
reason for the change in practice. Literature that is high in level and quality adds substantial 
validity, strength, and merit to the new EBP standard, and this leads to improved patient quality 
and safety outcomes.  
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Step V, developing an EBP standard, will be completed by the team members of the 
project which includes the project leader, DNP Student, two primary care providers that will 
serve as project champions, a project preceptor who is the quality and compliance director, and 
a risk management director.   
Step VI, implement the EBP, includes the execution of the written guidelines specific to 
the triggered problem. This phase necessitates the translation and application of evidence into 
practice. This process will include a multidisciplinary approach between team members, direct 
care providers, and organizational leaders.  
Step VII, evaluation, will be ongoing during and after the implementation of the new EBP 
practice change. Internal individual baseline HbA1C data has been gathered prior to the launch 
of this 8-week pilot in order to evaluate the outcome of the new evidence-based practice 
change. This is essential to allow stakeholders and team members to see the value and 
contribution of applying evidence into practice.  
Strengths and Limitations of EBP Model for DNP Project 
  Strengths of the model include the use of a pilot program launch to address barriers, 
redesign implementation processes, and fine tune the written and practice standards toward a 
final EBP protocol. Within the model are continuous feed-back, check and balance loops that 
evaluated different points as one proceeds through the steps. The inclusion of these key 
decision points are specific to this model, and help guide the project leader and the project team 
members to make determinations about the overall progression of the project. This process 
supports a project that is focused and valid, and one that is most likely to succeed and be in 
alignment with organizational priorities. An example within the model is a question that is posed: 
Is there sufficient research regarding the use of mobile phone applications for self-management 
of T2DM?  If there is not sufficient research to support this theme then one may choose to 
conduct a study or choose a different problem. This check and balance system is infused 
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throughout the model to ensure the team efforts are not futile and will lead to a productive new 
practice change that is evidence-based.  
 The limitation of this model is the focus of a team approach to bring the new practice 
change to fruition. In a rural healthcare setting, resources, including nursing staff are not 
abundant by any means. Due to lack of resources and inadequate staffing many are reluctant to 
join a team of any kind, especially over a long period of time. Many feel overwhelmed with work 
and the addition of team involvement is perceived as additional work and commitment. Based 
on personal experience as a leader in other service excellence programs, it is best to keep the 
team small in a rural health setting. Dissemination of the new practice change may be a 
different story, but the planning, developing, and implementing will need to be kept to an 
intimate group of team members. The practice change will be instituted in the primary care 
office settings and not the organization as a whole. As reimbursement transitions from volume 
to value in which quality trumps quantity, HbA1C reduction and diabetic control is going to be 
critical to maintain a viable practice within a healthcare setting (Bondurant & Armstrong, 2016). 
Literature Search  
 An exhaustive literature search was conducted within the electronic databases Cochrane 
Library, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Joanna Briggs 
Institute, Medline with full text via EBSCO, U.S. Preventative Services Task Force (USPSTF) 
PsycINFO, and Turning Research Into Practice (TRIP). Citation chasing of a single-arm 
feasibility study by Koot et al. (2019) was completed and resulted in a relevant SR and meta-
analysis by Bonoto et al. (2017). A hand search was completed in the Journal of Medical 
Internet Research (2016) and one article was found to be significant in the creation of this EBP 
project. 
 Keywords from the PICOT question were used in each respective database. Initial 
searches included several variances of those keywords to lead to a suitable relevant evidence 
search. The following keywords, phrases, Boolean Operators, and truncation options in various 
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combinations were used to retrieve the best evidence within each respective database; “mobile* 
phone” OR “mobile* app*” OR “cell* phone” OR “mobile application*” OR “smart phone” AND 
diabetes* OR diabetic* OR “diabetes mellitus”.  
Inclusion criteria were adult patients with T2DM who utilized mobile phone applications 
to foster ADA-approved diabetic self-care activities such as medication compliance, blood sugar 
monitoring efforts, and physical activity engagement to reduce HbA1C levels. Self-care 
perception was noted as a theme throughout the literature, therefore, studies that addressed 
self-care perception related to the use of MHAs for diabetic self-care were included. Limiters 
were peer-reviewed, research articles or Cochrane Reviews in English language conducted 
between January 2014 and June 2019. Exclusion criteria were children and adults with 
gestational diabetes, prediabetes, T1DM, and other telehealth technologies that were not MHA 
focused. Some of the evidence included data on theses exclusion grouping (Alharbi et al., 2016; 
Bonoto et al., 2017; Clement et al., 2018; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Mann, 
2018; Pamaiahgari, 2018; Whitehead & Seaton, 2016; Wu et al., 2017; Wu, Guo, & Zhang, 
2019; Yoshida et al., 2018), but subgroup analysis data were extracted when available from the 
literature to focus on the evidence related to inclusion criteria (Bonoto et al., 2017; Clement et 
al., 2018; Hou, Carter, Hewitt, Francisa & Mayor, 2016; Pal et al., 2014; Wang, Xue, Huang, 
Huang, & Zhang 2017; Whitehead & Seaton, 2016; Wu et al., 2017; Wu, Guo, & Zhang, 2019; 
Yoshida et al., 2018). Search of the CINAHL database produced 47 sources that had varying 
degrees of level, relevance and quality. References were read in two-phase process, first by 
reviewing titles and abstracts, and then by reviewing the full article, and five sources were 
selected. These sources were one meta-analysis of RCTs (Yoshida et al., 2018), one 
systematic review of RCTs (Whitehead & Seaton, 2016) , two SRs and combined meta-analysis 
of RCTs (Pal et al., 2014; Hou, Carter, Hewitt, Francisa, & Mayor, 2016), and one integrative 
review of RCTs with four group pre-post-test studies (Fu, McMahon, Gross, Adam, & Wyman, 
2017). The Cochrane Library yielded 73 sources and none were applicable to the focus of this 
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project. Additional pieces of evidence were excluded due to redundancy and lack of relevance 
to the focus of this project. Joanna Briggs Institute database resulted in 17 sources and three 
evidence summaries were selected for relevance (Mann, 2018; Nguyen, 2018; Pamaiahgari, 
2018). Medline with full text EBSCO yielded 242 sources, and after applying a two-phase 
evaluation process a total of four evidence sources were found (Wu et al., 2017; Wu, Guo, & 
Zhang, 2019; Cui, Wu, Mao, Wang, & Nie, 2016; Wang, Xue, Huang, Huang, & Zhang, 2017). 
The two-phase evaluation process consisted of reviewing abstracts followed by a more in-depth 
analysis of each respective article. The pieces of evidence included one SR (Wu et al., 2017), 
two SRs with combined meta-analysis (Wu, Guo, & Zhang, 2019; Cui, Wu, Mao, Wang, & Nie, 
2016), and one integrative review (Wang, Xue, Huang, Huang, & Zhang, 2017). This database 
search results included five articles duplicated from previous database. It was noted that other 
researchers within the literature searched the database PsycINFO within the articles, so this 
database was added to the search. The search of PsycINFO yielded 14 sources, in which none 
were relevant to this EBP project. Turning Research Into Practice (TRIP) clinical practice 
guideline database was utilized and yielded 10 sources, one clinical practice guideline was 
found to be relevant and qualified for inclusion into the pool of evidence (Clement et al., 2018). 
Finally, the U.S. Preventative Services Task Force (USPSTF) was included in the search, which 
resulted in two sources; however, neither was found to be relevant to this EBP project. In 
addition to searching the databases, citation chasing through a related article (Koot et al., 2019) 
outside of database-retrieved evidence, yielded 2 significant pieces of evidence (Bonoto et al., 
2017; Cui, Wu, Mao, Wang, & Nie, 2016). Hand searching efforts were completed in the Journal 
of Medical Internet Research, Volume 18, 2016 to 2017, on related articles and yielded one 
significant piece of evidence (Alharbi et al., 2016). This particular year was selected in the hand 
search process due to the amount of new literature that was in support of MHAs for the support 
of chronic disease such as diabetes.  
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An exhaustive search of the literature resulted in 15 pieces of evidence involving the 
effect of MHAs to reduce HbA1C in patients with T2DM and perceptions of self-care in the 
management of T2DM. Using the leveling system by Melnyk & Fineout-Overholt (2015), 12 of 
the sources included were deemed level 1 evidence, and were either systematic reviews, 
evidence summaries, or systematic reviews combined with meta-analysis. Two pieces were 
deemed level II evidence and consisted of integrated reviews. One piece of evidence was a 
clinical practice guideline which was deemed level VII. The included 15 sources was comprised 
of three evidence summaries (Mann, 2018; Nguyen, 2018; Pamaiahgari, 2018), one meta-
analysis (Yoshida et al., 2018), eight systematic reviews (Wu et al., 2017; Whitehead & Seaton, 
2016; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Cui, Wu, Mao, Wang, & Nie, 2016; Alharbi 
et al., 2016; Wu, Guo, & Zhang, 2019; Pal et al., 2014; Bonoto et al., 2017), two integrative 
reviews (Fu, McMahan, Gross, Adam, & Wyman, 2017; Wang, Xue, Huang, Huang, & Zhang, 
2017), and 1 clinical practice guideline (Clement et al., 2018) (see Table 2.1).  
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Table 2.1  
Literature Search Results 
 
Database Keyword(s) Limiters Date 
Restraints 
Results Relevant 
Evidence 
      
CINAHL (Subject 
Heading: 
Diabetes 
Mellitus, Type 
2.  “mobile* 
phone” OR 
“mobile app*” 
OR “mobile 
application*” 
OR “cell 
*phone” OR 
“smart phone”). 
English Peer 
Reviewed 
Research 
article 
May 2014-
June 2019 
47 5 (1 Meta-
Analysis of 
RCTs, 1 
Systematic 
Review, 2 
Systematic 
Reviews and 
Meta-
Analysis, 1 
Systematic 
Review of 
RCTs and 4 
group pre-
post-test). 
 
Citation 
Chase Koot 
et al., 2019 
 English Peer 
Reviewed 
May 2014-
June 2019 
2 2 (Systematic 
Reviews and 
Meta-Analysis 
of RCTs). 
 
Cochrane 
Library 
(Diabetes 
Mellitus, type 2, 
Explode all 
trees). 
Cochrane 
Reviews 
May 2014-
June 2019 
73 0(Redundancy 
of evidence or 
not relevant to 
topic). 
 
Hand Search 
Journal of 
Medical 
Internet 
Research 
 English Peer 
Reviewed 
Volume 18-
2016 
1 1 (Systematic 
Review and 
Meta-Analysis 
of RCTs). 
 
Joanna 
Briggs 
Institute 
(diabetes 
mellitus, type 2 
diabetes, 
mobile phone, 
application, 
app, 
smartphone, 
cell phone). 
 
English Peer 
Reviewed 
May 2014-
June 2019 
17 3 (Evidence 
Summaries). 
Medline with 
Full text via 
EBSCO 
(“mobile*phone” 
OR “mobile* 
app” OR “cell” 
phone” OR 
English Peer 
Reviewed 
Research 
article 
May 2014-
June 2019 
242 3 (Systematic 
Review and 
Meta-
Analysis, 
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“mobile 
application*” 
OR “smart 
phone” AND 
diabetes* OR 
diabetic* OR 
“diabetes 
mellitus”). 
1 Systematic 
Review of 
RCTs, 
1 Systematic 
Review of 
RCTs and 
Quasi-
experiments). 
 
PsycINFO (Thesaurus: 
Diabetes 
“mobile*” phone 
OR “mobile 
app*” OR “cell* 
phone” OR 
“smart phone”). 
English Peer 
Reviewed 
May 2014-
June 2019 
14 0 (none 
related to 
mobile phone 
applications’ 
impact on 
clinical 
outcome or 
self-care 
perception). 
 
TRIP Turning 
Research 
Into Practice 
 
(smart phone 
diabetes). 
Clinical 
Practice 
Guideline 
May 2014-
June 2019 
10 1 (Clinical 
Practice 
Guideline). 
USPSTF 
U.S. 
Preventative 
Services 
Task Force 
(Diabetes 
Metabolic). 
 May 2014-
June 2019 
2 0 (published 
article for 
screening 
adults for 
diabetes. 1 
article for 
screening for 
gestational 
diabetes). 
______________________________________________________________________________ 
Levels of Evidence 
 The level of evidence was evaluated by using the Pyramid of Evidence by Melnyk & 
Fineout-Overholt (2015). The Pyramid of Evidence is made-up of a seven-layer leveling system. 
Level 1 starts at the top of the pyramid and is indicative of the highest, strongest, and most 
reliable evidence. The leveling systems goes down the pyramid in succession to level II through 
level VII with level VII being the weakest sources of evidence. Included in level I are systematic 
reviews and meta-analysis of RCTs. Including level I evidence in an EBP practice would be 
considered gold-standard, however not all themes and projects are supported by level I sources 
(Melnyk & Fineout-Overholt, 2015). The fact that a study is located lower on the Hierarchy of 
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Evidence does not necessarily mean that the strength of recommendation made from that and 
other studies is low. When evidence shows consistency or is very compelling across studies, 
strong recommendations can be made from evidence found in studies even with lower levels of 
evidence (Melnyk & Fineout-Overholt, 2015). In other words, strong recommendations can be 
made from lower levels of evidence, and may be sufficient in the development of an EBP project 
leading toward a change in practice. Level II is just below Level I evidence on the pyramid and 
this includes RCTS that have solid design and methodology. Next is level III and it is made up of 
evidence from nonrandomized controlled trials. Level IV is inclusive of case-control or cohort 
studies. Level V encompasses evidence from systematic review of descriptive studies and/or 
qualitative studies. Level VI contains evidence from a single descriptive or qualitative study. 
Finally, Level VII is comprised of evidence from expert opinions, authority opinions, or 
guidelines (Melnyk & Fineout-Overholt, 2015). The Pyramid of Evidence was used as a leveling 
tool to determine the strength of evidence used for this EBP project, as well as, to add clarity 
and structure to the overall evaluation process. Additionally, the use of this tool demonstrates to 
the reader the comprehensive hierarchical level of support for this EBP project.  
Appraisal of Relevant Evidence 
 Appraisal of the included studies was completed through the use of the Critical Appraisal 
Skills Programme (CASP) tool. This tool is not meant to replace considered thought and 
judgement, but for use as a guide and to aid memory. All CASP checklists cover three main 
areas: validity, results, and clinical relevance (Critical Appraisal Skills Programme, 2018). The 
overall quality of the evidence body was mainly made up of systematic reviews and meta-
analysis of RCTS. Additionally, 2 integrated reviews were included in the evidence, as well as, 1 
clinical practice guideline. The clinical practice guideline was appraised by use of the Appraisal 
of Guidelines for Research & Evaluation II (AGREE II) tool.  
The CASP tool provided a clear structured path to critically appraise the studies used for 
this project. The appraisal tools add an overall quality rating for each source of evidence. 
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Quality rankings will be designated by using rankings of low, medium, and high. In general, 12 
of the included sources of evidence received a high quality rank due to the soundness of 
design, methodology, statistical analysis, and relevance to mobile phone application impact on 
HbA1C and promotion of self-care practices.  
Clinical practice guidelines are systematically developed statements to assist practitioner 
and patient decisions about appropriate health care for specific clinical circumstances 
(Brouwers et al., 2010). They play an important role in health policy formation and system-
related decisions that include health care practice across the illness-wellness continuum. 
Guidelines are only as good as their overall quality and rigor contained within the context of the 
practice standard. The Appraisal of Guidelines for REsearch & Evaluation (AGREE) Instrument 
was developed by an international team of guideline developers and researchers, known as the 
AGREE Collaboration, and was established to create a generic instrument to assess the 
process of guideline development, and the reporting of this process within the guideline 
(Brouwers et al., 2010). The domain scores are useful for comparing guidelines and will inform 
whether a guideline should be recommended for use to address the issue of variability in 
guideline quality, and has since then been refined. This refinement has resulted in the new 
AGREE II and is purposed for providing a framework to assess the quality of guidelines; provide 
a methodological strategy for the development of guidelines; and inform what information and 
how information ought to be reported in guidelines. Furthermore, the AGREE II assesses the 
methodological rigor and transparency in which a guideline is developed. The international 
consortium has not set minimum domain scores or patterns of scores across domains to 
differentiate between high quality and poor quality guidelines. These decisions should be made 
by the user and guided by the context in which AGREE II is being used (Brouwers et al., 2010). 
After appraisal of the clinical practice guideline it was determined that it was of moderate quality 
due to the lack of information in the domains of rigor and applicability.  
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Level I Evidence   
 Systematic reviews, SRs with associated meta-analysis, meta-analysis, and evidence 
summaries (Wu et al., 2017; Whitehead & Seaton, 2016; Hou, Carter, Hewitt, Francisa, & 
Mayor, 2016; Cui, Wu, Mao, Wang, & Nie, 2016; Alharbi et al., 2016; Wu, Guo, & Zhang, 2019; 
Pal et al., 2014; Bonoto et al., 2017; Yoshida et al,. 2018; Mann, 2018; Nguyen, 2018; 
Pamaiahgari, 2018) included in this project were all level I evidence according to the Pyramid of 
Evidence (Melnyk & Fineout-Overholt, 2015), and CASP quality ratings of high due to the 
design and methodology of respective pieces of evidence. In all, the level and quality of the 
evidence will add merit, value, and reliability to this EBP project, and shows a great amount of 
support for the use of MHAs to attain glycemic efficacy, not to mention, supports the 
improvement of self-care perception of T2DM patients. 
Level II Evidence          
 The integrative reviews included in this project (Fu, McMahan, Gross, Adam, & Wyman, 
2017; Wang, Xue, Huang, Huang, & Zhang, 2017) were deemed level II evidence according to 
the Pyramid of Evidence, and CASP quality ratings of moderate and high respectively due to the 
design and methodology of each piece of evidence. Again, this level and quality of evidence will 
add merit value and reliability to this EBP project. These pieces shows support for the use of 
MHAs for the reduction of HbA1C, and positive outcomes were noted related to the reaching 
glycemic efficacy. 
Level VII Evidence 
 A clinical practice guideline by Clement et al. (2018) recommended the use of telehealth 
technologies, including mobile phone applications, to improve self-management in underserved 
communities, facilitate consultation with specialized teams as part of a shared-care model, 
improve clinical outcomes in T2DM, decrease HbA1C results, increase in quality of care, 
decrease health service use and cost, increase patient satisfaction and knowledge, and 
improved glycemic and cardiovascular risk factor control. The clinical practice guideline 
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(Clement et al., 2018) was deemed level VII on the Pyramid of Evidence (Melnyk & Fineout-
Overholt, 2015), and an AGREEII quality rating of moderate due to lacking information in two of 
the six domains (Brouwers et al., 2010). (See Table 2.2). 
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Table 2.2  
Evidence 
 
Authors/ 
Purpose 
 
 
Population/ 
Duration 
 
Intervention(s) 
/Design 
 
Finding/ 
Results 
 
LOE/ 
Appraisal 
Alharbi et al., 
(2016) 
 
The object of 
this study was to 
assess the 
impact of 
information 
technology on 
changes in the 
levels of HbA1C. 
40,454 
participants. 
 
Half of the 
studies only 
included T2DM. 
The other half 
included T2DM 
and T1DM 
 
Study duration 
range 3-36 
months. 
 
Adults and 
children. 
Systematic 
Review/Meta-
Analysis, 32 
RCTs. 
 
Information 
technology 
including mobile 
phone 
applications, 
which 
demonstrated 
the largest 
reduction of 
HbA1C. 
 
Intervention 
groups received 
selected types of 
technology to 
support diabetic 
management. 
Controls 
received 
standard 
diabetic 
education.  
 
HbA1C changes 
with the use of 
MHA and 
telemedicine. 
 
Resulted in a         
-0.50% 
reduction in 
HbA1C (95% 
C1). 
 
MHAs and 
telemedicine 
analyses were 
not reported 
individually.  
Level I 
 
High 
Bonoto et al., 
(2017) 
 
The aim of the 
study was to 
evaluate to 
efficacy of MHA 
to assist the 
treatment of 
diabetic patients. 
1.264 
participants. 
T1DM and 
T2DM. 
 
Study duration 
1-2 months. 
 
Adults and 
children.  
Systematic 
Review/Meta-
Analysis, 12 
RCTs. 
 
Intervention 
group received 
MHA to support 
diabetic 
management. 
Controls 
received 
standard 
education. 
Use of MHAs 
reduced HbA1C 
by -0.44% (95% 
CI). 
Level I 
 
High 
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Clement et al., 
(2017) 
 
Diabetes Clinical 
Practice 
Guideline 
T1DM and 
T2DM. 
 
Adults and 
Children. 
Clinical Practice 
Guideline. 
 
109 references 
were included. 
Multiple 
systematic 
reviews and six 
addressing 
MHAs, 
telehealth, tele-
monitoring, e-
learning, 
teleconference, 
website, and 
internet.  
 
Recommend 
telehealth, 
including MHAs 
be used to 
improve self-
management of 
DM.  
 
MHAs were not 
endorsed over 
other 
technologies.  
Level VII 
 
Moderate 
Cui, Wu, Mao, 
Wang & Nie 
(2016) 
 
The object of 
this study was to 
assess the effect 
of MHA on 
change in 
HbA1C, weight, 
and lipids.0.013-
0.027 
 
1.022 
participants 
T2DM. 
Systematic 
Review/Meta-
Analysis, 13 
RCTs 
MHAs pooled 
effect on 
reduction of 
HbA1C was -
0.40% (95% CI). 
Level I 
 
High 
 
Fu, McMahon, 
Gross, Adam, & 
Wyman (2017). 
 
This study aims 
to describe the 
usability and 
clinical 
effectiveness of 
diabetes apps 
related to 
HbA1C. 
905 participants 
in the clinical 
effectiveness 
arm (T2DM). 
 
59 participants 
in the usability 
arm of the study. 
 
Study duration 
2-12 months. 
 
Adults 
Integrative 
Review 19 
RCTs, 1 pre-
post-test design 
Limited evidence 
to support the 
effectiveness of 
MHA to improve 
glycemic control. 
 
HbA1C 
reduction from 
0.15% to 1.9% 
(p<0.013-0.027). 
 
Bias due to 
combining other 
interventions. 
 
Subgroup 
analysis not 
reported. 
 
Level II 
 
Moderate 
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Hou, Carter, 
Hewitt, Francisa, 
& Mayor (2016). 
 
The aim of this 
study was to 
investigate the 
effect of MHAs 
on HbA1C. 
1,360 
participants 
T1DM and 
T2DM. 
 
Study duration 
3-12 months. 
 
Adults and 
Children 
 
Systematic 
Review/Meta-
Analysis 13 
RCTs 
Evidence 
indicated 
reduction in 
HbA1C use and 
MHA was 0.49% 
(95% CI). 
 
After excluding 
subgroups of 
poor findings, 
HbA1C 
reduction was 
0.41% (95% CI). 
Poor findings 
were studies 
with a reduction 
higher than 
expected, which 
questioned 
legitimacy of the 
findings. 
 
Ten studies of 
T2DM resulted 
in consistent 
0.50% HbA1C 
reduction (95% 
CI). 
 
Level I 
 
High 
Mann, E. (2018). 
 
To determine 
the effectiveness 
of self-
management 
education for 
those with DM. 
65,456 
participants 
T1DM and 
T2DM. 
 
Study duration 
6-12 months. 
 
Adults and 
Children. 
Evidence 
Summary. 
Those with DM 
should receive 
education that 
includes taking 
medications, 
monitoring 
glucose, and 
problem-solving. 
 
Education 
included self-
management 
with MHAs 
 
Level I 
 
High 
     
Nguyen, P. 
(2018). 
 
To determine 
the best 
evidence 
regarding self-
3,783 
participants 
T2DM. 
 
Study duration 
3-12 months. 
Evidence 
Summary 
Self-monitoring 
of blood glucose 
is an integral 
part of DM 
management. 
MHA research 
supported in the 
Level I 
 
High 
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monitoring of 
blood glucose. 
 
body of 
evidence that 
was foundational 
for this summary 
     
Pal, et al., 
(2014).  
 
This study 
aimed to 
evaluate the 
impact of 
computer-based 
DM self-
management 
interventions of 
health status 
and quality of 
life. 
3,578 
participants 
T2DM. 
 
Study duration 
10 minutes – 18 
months. 
 
Adults 
Systematic 
Review/Meta-
Analysis, 16 
RCTs. 
 
Intervention 
included MHAs, 
clinic education, 
and internet. 
Mobile phone 
subgroup had 
the largest effect 
on glucose 
control, 
compared to 
other computer-
based 
intervention. 
Pooled effect for 
this mobile 
phone subgroup 
was an HbA1C 
reduction of 
0.50% (95% CI). 
 
Level I 
 
High  
Pamaiahgari, P. 
(2018). 
 
To determine 
the best 
evidence for the 
use of eHealth in 
the management 
of DM. 
8,124 
participants 
T1DM and 
T2DM. 
 
Study duration 
3-12 months. 
 
Adults and 
Children. 
Evidence 
Summary 
Best practice 
recommends 
that mobile-
based support 
programs should 
be considered in 
the management 
of DM in a rural 
or remote 
setting. 
 
Level I 
 
High 
Wang, Xue, 
Huang, Huang & 
Zhang (2017). 
 
The aim of this 
study was to 
determine the 
effectiveness of 
mobile devices 
on technology 
interventions on 
obesity and DM. 
 
2.029 
participants 
obese or T2DM. 
 
Study duration 1 
week – 24 
months. 
 
Adults 
Integrative 
review 16 RCTs, 
8 Quasi-
experiments. 
 
Included MHAs, 
text messages, 
and portable 
monitoring 
devices. 
MHA subgroup 
resulted in a 
reduction with 
HbA1C, with the 
greatest 1.0% 
(p,0.001). 
Level II 
 
High 
Whitehead & 
Seaton (2016) 
 
This study was 
conducted to 
assess the 
Sample size 
range 48-288 
participants. 
T1DM and 
T2DM. 
 
Systematic 
Review, 9 RCTs. 
Significant 
improvement 
relating to the 
reduction of 
HbA1C in four of 
five studies. 
Level 1 
 
High 
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effectiveness of 
MHA on DM. 
Study duration 6 
weeks – 12 
months. 
 
Adults and 
children. 
Improvement 
was found to be 
statistically 
significant. 
 
Results were 
HbA1C 
reduction of 
0.40% (p < 
0.019) to 1.9 (p 
< 0.001). 
 
Wu et al., 
(2017). 
 
The aim of this 
study was to 
develop and 
validate 
taxonomy, 
investigate 
glycemic control, 
and explore 
contributions of 
different MHA 
functions related 
to the reduction 
of HbA1C. 
974 participants 
T1DM and 
T2DM 
 
Study duration 
3-12 months. 
 
Adults and 
Children. 
Systematic 
Review, 12 
RCTs. 
MHAs were 
associated with 
a clinically 
significant 
reduction of 
HbA1C 0.48 % 
(95% CI). No 
excessive 
adverse effects 
noted. 
 
Larger 
reductions of 
HbA1C were in 
T2DM group. 
 
Having a 
complication 
prevention 
module in the 
MHA was 
associated with 
a greater 
reduction 1.13% 
(95% CI) versus 
without. 
 
Inclusion of 
clinical decision 
function did not 
reduce HbA1C. 
 
Level I 
 
High 
Wu, Guo, & 
Zhang (2019). 
 
This study 
aimed to 
synthesize the 
clinical evidence 
2.526 
participants 
T1DM and 
T2DM. 
 
Study durations 
3-12 months. 
Systematic 
Review, 26 
RCTs. 11 
specific to 
T2DM. 
Use of MHA 
showed an 
HbA1C 
reduction of 
0.48% (95% CI). 
 
Level I 
 
High 
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of the efficacy of 
MHAs for 
lifestyle 
modification in 
different 
diabetes 
subgroups. 
Strong evidence 
for the efficacy 
of MHAs for 
lifestyle 
modification in 
T2DM. Evidence 
inconclusive for 
other diabetes 
subgroups. 
 
Yoshida et al., 
(2018). 
 
This study 
aimed to 
determine the 
effect of HIT on 
HbA1C. 
3.982 
participants 
T2DM. 
 
Study duration 
2-12 months. 
Meta-analysis, 
34 RCTs. 29 
specific to 
T2DM. 
 
HIT included 
mobile phone, 
web-based, 
short message 
text, telephone, 
and video 
conference. 
HbA1C 
reduction due to 
health 
information 
technology (HIT) 
were found 
across all 
studies.  
 
MHAs had 
greatest pooled 
HbA1C 
reduction of  
-0.67% (95% 
CI). MHAs 
produced largest 
reduction effect. 
Level I 
 
High 
 
______________________________________________________________________________ 
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Synthesis of Critically Appraised Literature 
Technology 
Mobile health applications.  The use of MHAs have been found to be the most 
effective tool to promote self-care behaviors that reduce overall HbA1C levels. The reduction of 
HbA1C have been found in other means of diabetic self-management technologies, but MHAs 
proved to have the greatest reduction pattern (Pal, et al., 2014; Pamaiahgari, 2018; Cui, Wu, 
Mao, Wang, & Nie, 2016; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Wang, Xue, Huang, 
Huang, & Zhang, 2017; Wu et al., 2017; Whitehead & Seaton, 2016; Yoshida et al., 2018).  
Within in the literature it was noted that all individuals with diabetes should have diabetic 
education that includes topics such as healthy diet, being physically active, taking medication, 
and monitoring glucose (Mann, 2018; ADA, 2018). Nguyen (2018), indicates that a structured 
self-monitoring of blood glucose is more beneficial than non-structured. MHAs support the ADA 
(2018) recommendations that lead to improved HbA1C levels. Another systematic review found 
that HbA1C decreased more in the MHA-only group than in the control or group that received 
counseling as an intervention (Whitehead & Seaton, 2016). Overall, findings in the literature 
point to the use of MHAs for best practice toward efforts to reduce HbA1C levels compared to 
other forms of technology. Moreover, MHAs appeared to be moderately effective in promoting 
lifestyle changes, including daily physical activity and medication adherence (Cui, Wu, Mao, 
Wang, & Nie, 2016). 
Computer-based. In one study, computer-based or internet-based interventions to 
manage T2DM were shown to have a small benefit on HbA1Cs,  but less than the MHA 
subgroup (Pal, et al., 2014). Computer-based intervention was also supported by an additional 
systematic review, however in that study the effect of MHAs on HbA1C levels resulted in a 
0.40% reduction compared to a 0.2% reduction in the computer-based arm (Cui, Wu, Mao, 
Wang, & Nie, 2016). Yoshida et a. (2018) found that a computer-based intervention decreased 
HbA1C, however, in comparison MHAs produced a larger effect. Although MHA use has shown 
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to produce a greater decrease in HbA1C, where mobile-based programs are not available, 
computer-based programs should be considered for the management of T2DM (Pamaiahgari, 
2018).  
Text messaging. Text messaging was another form of technology that was identified in 
the literature (Wang, Xue, Huang, Huang, & Zhang, 2017; Yoshida et al., 2018). Text 
messaging was mainly used to provide knowledge and tips on diet, physical activity, and 
medications, whereas the MHA played a more concise role in disease control by providing 
feedback to reinforce positive behavior changes as well as serving as a data collection platform 
(Wang, Xue, Huang, Huang, & Zhang, 2017). The findings by researchers Wang, Xue, Huang, 
Huang, and Zhang (2017), that focused on T2DM indicated the greatest HbA1C reduction was a 
result of the use of MHAs rather than text messaging. Yoshida et al. (2018) found that text 
messaging decreased HbA1C, however, in comparison MHAs produced a larger effect.  
 Voice messaging. Voice messaging through use of automated services, interactive-
voice systems, teleconferencing, and telephone-based services were also compared to MHAs. 
Researchers (Alharbi et al., 2016; Bonoto et al., 2017; Cui, Wu, Mai, Wang, and Nie, 2016; Wu, 
Guo, and Zhang, 2019; Wu et al., 2017; Wang, Xue, Huang, Huang, Zhang, 2017; Yoshida et 
al., 2018) found that MHAs produced a larger reduction in HgA1C compared to these various 
voice messaging interventions. MHAs used in the studies (Alharbi et al., 2016; Bonoto et al., 
2017; Cui, Wu, Mai, Wang, and Nie, 2016; Wu, Guo, and Zhang, 2019; Wu et al., 2017; Wang, 
Xue, Huang, Huang, Zhang, 2017; Yoshida et al., 2018).  included functions that were geared 
toward fostering behavioral lifestyle modifications to improve self-care management of T2DM. 
This was a feature not available through typical voice messaging systems (Alharbi et al., 2016; 
Bonoto et al., 2017; Cui, Wu, Mai, Wang, and Nie, 2016; Wu, Guo, and Zhang, 2019; Wu et al., 
2017; Wang, Xue, Huang, Huang, Zhang, 2017; Yoshida et al., 2018).  
 Telehealth services. Telemedicine, telehealth, Video-phone chat, interactive-video 
systems, were compared to MHAs throughout the literature. Researchers found that the MHAs 
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demonstrated the largest reduction in HbA1C. Use of MHAs brought the greatest standardized 
decrease in HbA1C and produced the largest effect on glycemic control (Cui, Wu, Mai, Wang, 
and Nie, 2016; Wang, Xue, Huang, Huang, Zhang, 2017; Alharbi et al., 2016; Yoshida et al., 
2018).  
Technology used for diabetes self-management exists in the form of many different 
platforms, such as internet, telemedicine, teleconference, mobile phone SMS (texting), 
computer-based programs, and MHAs. Throughout the evidence used to develop this project, 
the use of MHAs showed a statistically significant reduction in HbA1C reduction (Alharbi et al., 
2016; Bonoto et al., 2017; Cui, Wu, Mao, Wang, & Nie, 2016; Hou, Carter, Hewitt, Francisa, & 
Mayor, 2016; Pal et al., 2014; Wang, Xue, Huang, Huang, & Zhang, 2017; Whitehead & Seaton, 
2016;  Wu, Guo, & Zhang, 2019; Wu et al., 2017; Yoshida et al., 2018).  
Outcomes 
Glycemic Efficacy 
 Glycemic control was consistently measured through HbA1C measurements throughout 
the literature, and is defined as a HbA1C level of less than 8.0 (ADA, 2018). The ADA (2018) 
suggests a more stringent HbA1C goal of < 6.5% if the patient can achieve this without 
significant hypoglycemia or adverse effects, and a less stringent goal  of  <8% if the patient has 
a history of hypoglycemia, limited life expectancy, long-standing diabetes, appropriate glucose 
monitoring, and effective doses of glucose lowering agents. For the purpose of this project and 
to err on the side of safety, the project will utilize the less stringent HbA1C goal of <8.0%. 
HbA1C is a significant indicator because it reflects glycemia over eight weeks of time (Alharbi et 
al., 2016), and has a strong correlation in the occurrence of diabetic complications and 
increased mortality rates in people with diabetes (Bonoto et al., 2017; Yoshida et al., 
2018). Glycemic control was statistically significant across most of the body of evidence that 
was included in the EBP project (Alharbi et al., 2016; Bonoto et al., 2017; Clement et al., 2018; 
Cui, Wu, Mao, Wang & Nie, 2016; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Nguyen, 2018; 
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Pal et al,. 2014; Pamaiahgari, 2018; Wang, Xue, Huang, Huang, & Zhang, 2017; Whitehead & 
Seaton, 2016; Wu et al., 2017; Wu, Guo, & Zhang, 2019; Yoshida et al., 2018). The exception 
was the limited evidence reported by Fu, McMahon, Gross, Adam, & Wyman (2017), the 
findings of which were believed to be due to confounding variables that infused the results with 
bias. However, HbA1C reduction was still found by the researcher, but were not statistically 
significant.   
 Alharbi et al. (2016) conducted a systematic review of  30 RCTs and concluded that by 
using MHAs, telemedicine, web-based, and telephone-based interventions, participants 
achieved significant reduction in HbA1C. T2DM participants that used these electronic self-
management technologies found the greatest impact on HbA1C reduction, which resulted in a -
0.50% reduction of HbA1C (95% CI). Subgroup analysis was not included in this study so it is 
not clear which specific technologies had the greatest effect. Bonoto et al. (2017) concluded that 
the use of MHAs by adult T2DM participants could help improve the control of HbA1C. Of the 13 
RCTs included in their study, six of them produced statistically significant reductions in HbA1C 
values. The meta-analysis of those studies resulted in a mean HbA1C reduction difference of -
0.44 (CI -0.59 to 0.29 p < 0.001). Cui et al. (2016) concluded that there was a moderate effect 
on glycemic control after the mHealth app-based interventions. The overall effect on HbA1C 
showed a mean reduction difference of -0.40% (-4. 37 mmol/mol) (95% CI -0.69 to -0.11 p = 
0.007) and the standardized mean difference was -0.40 % (-4.37 mmol/mol) (95% CI -0.69 to - 
0.10% p = 0.008). Fu et al. (2017) concluded that MHAs that were used in the studies of their 
review reduced HbA1C, ranging from 0.15-1.9% from baseline. Statistical significance was 
found in four of the studies within the integrative review. The greatest interactive features were 
those included the application’s design and consisted of MHA used in conjunction with a 
Bluetooth® enabled smart-glucometer, direct provider feedback capability, and website access. 
Hou et al. (2016) found that in all of the studies in their review, mean reduction of HbA1C was 
0.49% (95% CI  0.30, 0.68 p = <0.01). These results exhibited consistent findings with no 
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heterogeneity. After excluding subgroups of skewed findings, a mean reduction of 0.41% was 
found (95% CI 0.22, 0.61; p <0.001 I=0%). An example of a subgroup study with skewed 
findings that was excluded, was one that found a significantly higher reduction in HbA1C than 
any of the other studies included in the review. The researchers (Hou et al., 2016) concluded 
that the applications improved self-management by providing personalized feedback on self-
monitoring data such as blood glucose, food intake, and physical activity. Additionally, the use 
of the MHAs resulted in decreased consultation times. Pal et al. (2014) concluded that the 
mobile phone subgroup had the largest effect on glycemic control compared to the other 
computer-based self-management interventions. Pooled effect for this subgroup was a HbA1C 
reduction of -0.50% (95% CI -0.7% to -0.3%). There was no evident improvement in depression, 
quality of life, blood pressure, serum lipids, or weight in this study. Pamaiahgari’s (2018) best 
practice recommendations indicate that mobile-based support programs, including MHAs, 
should be considered in the management of diabetic patients where available. Where mobile-
based programs are unavailable, computer-based programs should be considered. The review 
by Wang et al. (2017) included five studies that used MHAs, which resulted in a reduction in 
HbA1C with the largest reduction being 1.0% at a 12-month follow up period. Whitehead et al. 
(2016) concluded statistically significant improvements in the reduction of HbA1C in two of the 
three studies included in their review that specifically focused on T2DM participants (-0.40 p = 
0.019, -1.9% p = 0.001). Moreover, the use of MHAs has the potential to improve health 
outcomes among those living with chronic diseases such as T2DM. Wu, Guo, & Zhang (2019) 
concluded that there is strong evidence for the efficacy of mobile phone applications for lifestyle 
modification in type 2 diabetes. This systematic review and meta-analysis conducted a 
subgroup analysis specific to adult T2DM participants. In the short-term effect group that 
showed virtually no heterogeneity, the MHAs group produced a -0.48 ( 95% CI -0.69 to -0.28) 
reduction in HbA1C. In the long-term group HbA1C reduction was -0.25 (95% CI -0.43 to -0.07) 
and both groups resulted in statistically significant reduction in HbA1C. The results were 
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inconclusive for the other diabetes subtypes. Wu et al. (2017) researchers concluded that using 
MHA interventions were associated with a clinically significant reduction of HbA1C  with a mean 
difference of 0.48%  (95% CI 0.19%-0.78%) without excess adverse events. The larger 
reductions of HbA1C were found among patients with T2DM. Having a complication prevention 
module in app-based interventions was associated with a greater HA1C reduction (MD 1.31%, 
95% CI 0.66%-1.96%) versus without. Yoshida et al. (2018) completed a systematic review that 
included 16 RCTs and eight quasi-experiments and they found the overall reduction effect was -
0.63. MHAs had the greatest pooled standardized decrease in HbA1c reduction of -0.67 (-0.90, 
- 0.45). On average, MHA interventions produced larger effects compared to other forms of 
approaches. These researchers concluded that the findings from the meta-analysis suggest that 
health information technology, including MHAs, led to improvement of glycemic control. 
Self-Care Behaviors   
 The ADA (2018) speaks to reaching glycemic efficacy through self-care behaviors such 
as monitoring blood sugars, physical activity engagement, and adherence to prescribed 
medications for those who suffer from chronic diseases such as diabetes. Cui, Wu, Mao, Wang, 
& Nie (2016) concluded that MHAs offer moderate benefits to T2DM self-management. These 
researchers recommended a follow up period of greater than 12 months to evaluate the long-
term impact of MHAs for diabetes care and self-management. Mann (2018) determined best 
practice recommendations indicate that all individuals with diabetes should receive self-
management education that includes topics such as healthy diet, being physically active, taking 
medication, monitoring of glucose, reducing risk and complications, and problem solving. Self-
management education is recommended through the use of MHAs (Pamaiahgari, 2018; Wu, 
Guo, & Zhang, 2019; Wu et al., 2017). Nguyen (2018) indicated that self-monitoring is 
recommended as an integral part of diabetes self-management strategies. This evidence 
summary included a meta-analysis of RCTS in which the researchers found that compared to 
those who did not perform self-managed blood glucose (SMBG), individuals who performed 
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SMBG reduced HbA1C level by 0.17% (95% CI 0.25 to 0.09%, p <0.003). The comparison 
between structured and unstructured SMBG found a mean difference of HbA1C reduction of 
0.27% (95% CI  0.49 to 0.04%, p < 0.018). The conclusion favored structured SMBG which 
indicated a structured SMBG was found to be more beneficial than non-structured SMBG. 
Structured SMBG consisted of scheduled monitoring and recording of blood glucose for tracking 
and evaluation purposes. (Mannucci, Antenore, Giorgino, & Scavini, 2018). MHAs have 
provided a structured-electronic platform for the monitoring and recording of blood glucose in 
adults with T2DM that leads to improved glycemic control.  
MHAs that have the greatest interactive features which encourage blood glucose 
monitoring, physical activity engagement, and adherence to medication regimens are directly 
related to improvements in glycemic control glycemic control (Pal et al., 2014; Fu, McMahon, 
Gross, Adam, & Wyman, 2017; Mann, 2018; Nguyen, 2018). This provides a convenient 
reminder and documentation system that is more accurate then depending on memory alone. 
Pamaiahgari (2018) produced an evidence summary that recommended mobile-based support 
programs should be considered in the management of diabetic patients. Mobile-phone based 
interventions (including MHAs) were included in this recommendation. Other researchers have 
found that mobile phone interventions for diabetes self-management have been able to reduce 
HbA1C levels, and this may be related to the enhanced feedback and provider-patient 
interactions, the convenience of the MHA usage, the intensity of the intervention, or the 
behavior-change techniques instilled in the applications. Behavioral reminders through the use 
of MHAs  encourage blood sugar monitoring efforts and improve physical activity engagement 
(Cui, Wu, Mao, Wang, & Nie, 2016; Wu et al., 2017; Wu, Guo, & Zhang, 2019; Yoshida et al., 
2018; MyFitnessPal, 2019). Also included in the MHAs were behavior-change techniques or 
reminders to promote adherence to medication regimens. The use of MHAs interventions have 
suggested a moderate effect in promoting lifestyle changes, including daily physical activity and 
medication regimen adherence (Cui, Wu, Mao, Wang, & Nie, 2016; Clement et al., 2018; Hou, 
Mobile Application for Glycemic Control    37 
 
 
Carter, Hewitt, Francisa, & Mayor, 2016; Pamaiahgari, 2018; Wang, Xue, Huang, Huang, & 
Zhang, 2017; Wu et al., 2017; Wu, Guo, & Zhang, 2019; Yoshida et al., 2018). 
Self-Care Perception 
 MHA’s had a mixed impact on self-care perception for adults with T2DM (Bonoto et al., 
2017; Pal et al., 2014; Wu, Guo, & Zhang, 2019). Bonoto et al. (2017) found that MHAs seem to 
strengthen the perception of self-care by contributing better information and health education to 
the patient that ultimately boosts self-confidence to care for this devastating disease. Ultimately, 
self-confidence in personal care may support self-care behaviors for those with chronic 
diseases Bonoto et al. (2017) measured this using the  Disease-Specific, Quality-of-Life 
(DSQOL), Diabetes Quality of Life (DQOL), Diabetes Quality of Life for Youth (DQOLY) and 
Self-Care Revised 36-item Short-Form. Pal et al. (2014) found there was no evident 
improvement in self-care perception and various tools to measure this were not mentioned. 
Improved self-care perception was found to be strengthened by the MHAs ability to contribute to 
better information and health education, increased patient satisfaction, and increased self-
confidence to the user (Bonoto et al., 2017; Clement et al., 2018; Wu, Guo, & Zhang, 2019). 
Best Practice Model Recommendation 
         Best practice recommendations include a multi-functional, user-friendly MHA that is 
adaptable to the feedback of the provider (Wu et al., 2017; Nguyen, 2018; Mann, 2018; Fu, 
McMahon, Gross, Adam, & Wyman, 2017). Provider feedback included the use of MHAs, web-
based, computer-based, and telephone-based interventions. The iHealth® and Dario® smart 
glucometer bundles offer a mobile smartphone application that allows for individualized patient-
provider selected alert settings for reminders to check blood sugar, take medication, and 
engage in activity. Additionally, these bundles include a smart glucometer that pairs with mobile 
smartphone technology for convenient uploading and downloading of glucose readings, physical 
activity, and medication adherence practices (Dario® Blood Glucose Management System, 
2019; iHealth® Smart Wireless Gluco-Monitoring System, 2019). Moreover, the addition of a 
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MHA shows an improvement in the perception of self-care management behaviors such as 
blood glucose monitoring efforts, medication adherence, and physical activity engagement of 
adults with T2DM.  
Three options of MHAs were considered for this EBP. Regardless of the MHA selected it 
will include glucose monitoring capability, physical activity monitoring , and medication 
adherence monitoring. Notification alert  reminders for blood sugar monitoring, medication 
adherence and physical activity engagement will be patient-driven and individualized according 
to the specific need of each participant in regards to these activities. The overall functionality 
options of the MHA, provider feedback loop of communication, and the promotion of self-care 
practices can foster glycemic control and theoretically reduce incidence of diabetic complication 
and decreased mortality (Alharbi et al., 2016; Bonoto et al., 2017; Clement et al., 2018; Cui, Wu, 
Mao, Wang, & Nie, 2016; Fu, McMahon, Gross, Adam, & Wyman, 2017; Hou, Carter, Hewitt, 
Francisa, & Mayor, 2016; Mann, 2018; Nguyen, 2018; Pal et al,. 2014; Pamaiahgari, 2018; 
Wang, Xue, Huang, Huang, & Zhang, 2017; Whitehead & Seaton, 2016; Wu et al., 2017; Wu, 
Guo, & Zhang, 2019; Yoshida et al., 2018). The use of MHAs may also result in improved self-
care perception which may also contribute to improved self-care practices such as blood sugar 
monitoring efforts, adherence to medication regimens, and physical activity engagement.  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
The purpose of the EBP project was to evaluate the effectiveness of a diabetes-specific 
MHA on HbA1C and on self-care behaviors such as blood glucose monitoring efforts, physical 
activity engagement, and medication adherence. A secondary purpose of the EBP project was 
to evaluate cumulative self-care perception before and after the intervention. The 
implementation of EBP to drive practice changes is a challenging process and needs to 
strategically address organizational complexities, administrative leaders, clinicians, and 
ultimately the healthcare culture (Titler, 2001). Quality outcomes and positive patient 
experiences are demanded by consumers, required by payees, and transparently reported to 
the public (Creehan, 2015). Healthcare is changing at a rapid pace and the diffusion of evidence 
into practice is essential as the shift in quality and safety practices become the focus throughout 
all health organizations. This dynamic movement is not new and is becoming increasingly 
urgent as challenges related to both quality and cost persist (Bondurant & Armstrong, 2016). 
Doctorally prepared nurses are uniquely skilled and highly qualified to change practice by 
improving quality and safety and decreasing cost burden through the implementation of EBP.  
Setting and Participants 
Setting 
The EBP project was conducted at certified rural healthcare centers in northwest 
Indiana. The medical group consists of 13 primary healthcare providers. Six of the primary care 
providers are medical doctors and seven are family nurse practitioners. Five of the medical 
doctors are employed at the Winamac, Indiana location, while one is located at the North 
Judson, Indiana location. Four nurse practitioners are employed at the Winamac, Indiana 
location, while one is employed at each of the satellite offices in northwest Indiana. All of the 
providers provide care for patients with T2DM that fall within the inclusion criteria for this project. 
The project preceptor is the director of quality and compliance for the organization. She was 
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selected due to her expertise in quality and safety reporting that is mandatory when an 
organization accepts payment from the Centers of Medicare and Medicaid Services (CMS, 
2019) (M. Jones, personal communication, May 24, 2019). She has an associate’s degree in 
business administration, and has been employed with the organization for eight years. She has 
direct access to the EMR driven quality measures and was able to obtain the CMS specific 
outcome measures that indicated a high percentage of patients with HbA1C above 9.0.  
 The MHA project was led by a doctor of nursing practice (DNP) student who has a board 
certification as a Family Nurse Practitioner. Her career encompasses 28 years of nursing 
experience, which included a special interest in the management of adults with T2DM. The DNP 
student led the MHA pilot program with the assistance of two additional nurse practitioner 
champions, a project preceptor, and a corporate compliance/quality assurance leader. The 
project preceptor and the DNP student had initial meetings early on to determine the greatest, 
most pressing organizational need. Consultations were continuously made within the group to 
brainstorm and determine the best direction for the practice change. Practice champions 
included two nurse practitioners who have agreed to assist with the creation and implementation 
of the protocol (See Appendix A). The lead nurse practitioner at the healthcare center in 
Monterey, Indiana has been employed in family practice for 11 years. He completed his 
education at Valparaiso University and is a master’s prepared, board certified family nurse 
practitioner. The healthcare center is a rural satellite primary care practice that strives to offer 
high quality care to the local and surrounding communities. Additionally, the nurse practitioner of 
this clinic is a veteran who proudly served in the Army. He has been a nurse for over 20 years 
and has special interest in pain management and management of adults with T2DM. 
 A nurse practitioner at the Winamac healthcare center completed her education at 
Indiana State University, and is a master’s prepared, board certified family nurse practitioner. 
She has been employed as a family nurse practitioner in primary care for 3 years and strives to 
offer high quality care to the local and surrounding communities. She has been a nurse for over 
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20 years and has special interests in women’s health services and management of adult T2DM 
patients.  
Participants 
 The focus population was English reading and speaking patients that are 18 years and 
older within the organization’s medical group diagnosed with T2DM, having an HbA1C of 
greater than 8.0, and owners of a smart phone. Generally, middle aged individuals are more 
likely to have T2DM, but it has been found in obese children (ADA, 2018). For this project 
pregnant women and children were excluded, as well as those who did not own or have access 
to a mobile smart phone or tablet. Additionally, patients with dementia, addictions, or other 
mentally or physically incapacitating medical conditions were excluded.  
Pre-Intervention Group Characteristics. Demographic data were collected and 
recorded (See Appendix B) at a special initial start-up meeting using the participant information 
sheet (See Appendix C) to collect the participant’s age, date of birth, gender, race, years 
diagnosed with T2DM, current diabetes-specific medication, how often they normally engaged in 
physical activity, the email address of their provider, pre-intervention HbA1C, and their personal 
email address. This information will be used to assess the characteristics of the project sample 
to that of the adult T2DM in the general population. Twenty-five participants joined the project 
and seven were lost to attrition. The mean age for the group was 52.2 years  made up of five 
white males and 13 white females, and mean number of years of having the diagnosis of T2DM 
was 12.72.  
Intervention 
 The intervention consists of the use of a diabetes-specific MHA for the self-management 
of T2DM. The EBP practice program developed is called Living Sweet: An Adult Type II 
Diabetes Mellitus Management Program. The project will utilize a MHA platform to deliver self-
care behavior awareness toward the promotion glycemic control. The application selection 
process was a challenge due to the many different functionality qualities of the various 
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applications. For instance, most of them allow for logging blood sugar readings, recording 
physical activity events, and medication adherence trackers (MySugr®, 2019; Health2Sync®, 
2019; Diabetes Connect®, 2019). Multiple applications were evaluated for this project, however 
the one that was the most user friendly, cost-effective, technologically equipped, and aligned 
with ADA diabetes mellitus self-management recommendations was selected (ADA, 2018) 
The diabetes-specific MHA utilized for this project is MySugr®. The attractions of 
MySugr® diabetes-specific mobile health application is that it is cost-efficient, user-friendly, 
capable of monitoring the three different self-care behaviors that were evaluated in this project,  
Android® and iPhone® compatible, congruent with ADA (2018) self-management 
recommendations, and has the capability to upload and transfer or export the documented 
results electronically as a spreadsheet (MySugr®, 2019). In some cases, MHAs may not be 
advantageous for certain participants such as those with learning deficits (Fu, McMahon, Gross, 
Adam, & Wyman, 2017). To enhance usability for these participants, access to the DNP student 
project leader or designee will be offered throughout the entire project time span. The MHA will 
be used as a reminder system that will include patient-centered, individualized goals to 
encourage self-care behaviors such as blood glucose monitoring efforts, medication adherence, 
and physical activity engagement. Adherence will be assessed by determining the total number 
of met self-care behaviors each week. 
 Each participant was given a one-on-one enrollee learning session by the DNP student 
project leader. This session included a review of the participant information sheet (See 
Appendix C) education and demonstrations regarding the use of the MHA, as well as discussion 
about individual personal self-care behavior goals. In Addition, a pre-intervention self-care 
inventory-revised tool (See Appendix D) was completed to record self-care perception prior to 
the onset of using the MHA. This will help determine the impact of the intervention of participant 
self-care perception.  
Mobile Application for Glycemic Control    43 
 
 
Due to the nature of the sensitive information being discussed, 1-on-1 sessions were 
more fitting to minimize potential discomfort that may accompany a group setting. This session 
will allow participants to meet and build rapport with the DNP student project leader, received 
clear explanation of the program, allow for question and answer opportunities, obtain 
demographic information, complete the initial self-care revised-inventory tool, and determine 
personal goals for blood glucose monitoring efforts, physical activity engagement, and 
medication adherence.  
One challenge noted during the process was that the phones of participants were not 
current with phone updates. This resulted in the DNP student spending extra time assisting with 
the updating of the smart phones. This prompted a verbal reminder to each participant to update 
the operating system of their phone prior to the initial startup meeting. Additionally, this step was 
added to the protocol. In many cases participants could not remember the password that was 
connected to their smart phone application store. This was imperative, because without the 
password the application could not be downloaded. This certainly slowed the initiation process 
considerably and a prompt was added to the protocol to remind users to be aware of the 
password to their phones prior to the initial setup date.  In one case a participant did not own a 
smart phone, however she did own an Android© tablet which worked identical to the smart 
phone application. An isolated challenge included a participant that did not have an email 
address or password to her email. This is important when downloading applications because the 
personal email is used by the application to verify the identity of the person wanting to place it 
on their smart phone. There was a significant delay in the startup process for this participant 
because she had to connect with her daughter who set up the initial email and password for her 
smart phone. Again, a prompt was added to the protocol to remind users to be aware of the 
username and password to their personal email for verification purposes.  
 The program included a tracking form with built-in check points (See Appendix E) to 
determine if the participant has any questions or needs assistance troubleshooting the 
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application. These check points will occur at week 1, week 2, week 3, week 4, week 5, week 6, 
and week 7 to determine adherence and need for assistance and troubleshooting of the 
application (see Table 3.1). Check points and data exportation will occur on different dates for 
each participant due to staggered start to the program. Therefore, to direct participants to meet 
the weekly data exportation request to the DNP project leader and their respective primary care 
provider, reminders were written on a pre-printed calendar (See Appendix F) and given to each 
of them. During this time each participant has been instructed to electronically upload and 
export their recorded data to the DNP student project leader and primary care provider when 
applicable. In the event the DNP student project leader has not received exported data from a 
participant or participants at these designated time-frames or has missing data, a text or phone 
call will be completed. The scheduled check points will help to further guide and define the MHA 
program by heightening awareness of unforeseen barriers and variables that may deter 
adherence. Week 8 will be the completion of the program and includes an arranged meeting 
with the project leader. At this time a patient satisfaction survey (See Appendix G), a repeat self-
care inventory-revised tool (See Appendix D), and a post-intervention HbA1C will be completed 
to evaluate impact of MHAs on selected outcome measures. The potential benefits of the MHA 
program include HbA1C reduction, improved self-care behaviors, and improved self-care 
perception. Risks were not associated with the use of MHAs. However, lack of experience with 
technology and learning deficits may hinder the use of the application for some participants (Fu, 
McMahan, Gross, Adam, & Wyman, 2017).  
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Table 3.1  
Diabetes-specific MHA Program Outline 
Check Point                                                                 Topic      
    
 
Initial 
(Special Session) 
 
 
 
 
 
 
 
Check Point 1 
(Week 1) 
 
Check Point 2 
(Week 2) 
 
Check Point 3 
(Week 3) 
 
Check Point 4 
(Week 4) 
 
Check Point 5 
(Week 5) 
 
Check Point 6 
(Week 6)     
 
Check Point 7 
(Week 7) 
 
Check Point 8 
(Week 8) 
 
 
 
 
 
 
 
 
 
 
 
Program introduction. 
Document most recent HbA1C.  
Intervention education. 
Self-Care Inventory-Revised: Pre. 
Patient-driven goal determination 
of self-care behaviors entered into the app. 
Review participant information sheet. 
 
 
Assess adherence based on patient upload 
data. Troubleshoot. 
 
Assess adherence based on patient upload 
data. Troubleshoot. 
 
Assess adherence based on patient upload 
data. Troubleshoot. 
  
Assess adherence based on patient upload 
data. Troubleshoot. 
                                                               
Assess adherence based on patient upload 
data. Troubleshoot. 
 
Assess adherence based on patient upload 
data. Troubleshoot. 
 
Assess adherence based on patient upload 
data. Troubleshoot.  
 
Satisfaction Survey 
Self-Care Inventory-Revised: Post 
Obtain HbA1C: Post
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Comparison  
 The high percentage of HbA1C results greater than 9.0 within the medical group was the 
motivation for this project. In Quarter 1 of 2019, 59.3% of adult T2DM patients had an HbA1C 
greater than 9.0, and this trend rose in the second quarter to 66%. The outcome measure of 9.0 
is specifically requested by and reported to CMS as a quality indicator, and the medical group 
are not meeting the standard risking loss of reimbursement for services (CMS, 2019). 
Outcomes  
 Two major outcomes were evaluated for the diabetes-specific MHA intervention: (a) 
effect on HbA1C levels, and (b) effect on self-care behaviors. For this project, glycemic control 
is measured through obtaining  HbA1C by capillary blood tests comparing individuals’ results to 
prior test result to results after an 8-week MHA intervention. The statistical test used to evaluate 
the HbA1Cs was the paired t-test which is used to determine if the pre-intervention mean results 
are significantly different from the post-intervention mean results. The paired sample t-test, 
sometimes called the dependent sample t-test, is a statistical method used to determine 
whether the mean difference between two sets of observations is zero. In a paired sample t-test, 
each subject or entity is measured twice, resulting in pairs of observations (Statistic Solutions, 
2019). Frequency analysis expressed in percentage was used to examine weekly self-care 
behaviors goals that were met or not met (Statistic Solutions, 2019). Self-care behaviors will be 
evaluated based on self-selected individualized goals chosen by each participant. Individualized 
goal assessments will determine if the participant met or did not meet blood sugar monitoring, 
medication adherence, and physical activity engagement. A behavior tracking form was created 
to monitor individualized weekly self-care behavior goals (See Appendix H). Glucose 
monitoring, medication adherence, and physical activity were considered met if the participant 
recorded 100% of their self-selected goals, and not met if the participant recorded less than 
100% of their expected goals. As participants complete the self-care behaviors monitored in this 
project, then will be record results through manual data entry by tapping an icon specific to 
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medications, blood glucose monitoring, and physical activity within the MHA. This information 
will then be digitally exported to the DNP student project leader’s and participant primary care 
provider’s email for review.  
Self-care perception with use of MHAs were collected using the Self-Care Inventory-
Revised (SCI-R) tool (See Appendix D) completed before and after an 8-week MHA 
intervention. The SCI-R is a psychometrically sound measure of perceptions of adherence to 
recommended self-care behaviors of adults with T1 and T2DM (Weinger, Welch, Butler, & La 
Greca, 2005). The tool is a Likert-scale survey that allows for self-assessment of diabetes self-
care behaviors (Weinger, Welch, Butler, & La Greca, 2005). Through self-reporting what each 
participant achieves regarding diabetes-specific self-care behaviors over the previous 1-2 
months. Scoring of the survey quantifies reported behaviors in the following fashion: never = 1, 
rarely = 2, sometimes = 3, usually = 4, and always = 5. This tool was found to have sound 
reliability and validity through a psychometric analysis and reflects the internal consistency of 
the SCI-R tool (α = 0.87). Correlation with a measure of frequency of diabetes self-care 
behaviors  r = 0.63 supports concurrent validity of the SCI-R (Weinger, Welch, Butler, & La 
Greca, 2005). The statistical method that was used to evaluate pre- and post-SCI-R tool results 
was the paired sample t-test (Cronk, 2018). 
Time  
 Prior to the launch of this EBP project, three Power Point presentations were given to 
medical staff with a provider-specific information sheet (See Appendix I) to highlight project 
details and clarify the referral process. Following the EMR-directed referral (See Appendix J), a 
retrospective search of the referred participants within the EMR was completed to ensure 
participants met inclusion criteria. After inclusion criteria were confirmed, each participant was 
contacted, and a special meeting was arranged to initiate the MHA program. During this special 
meeting, a participant information sheet (See Appendix C) that clearly explains the program was 
reviewed, a pre-intervention SCI-R was completed, and the MHA was downloaded to each 
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participant’s mobile phone. Respective forms were developed to facilitate the introduction of the 
MHA program and keep the process consistent and reproducible. The implementation began on 
September 6, 2019. Successful completion consisted of being enrolled for 8 weeks of MHA 
usage and completing the post- intervention HbA1C, SCI-R, and satisfaction survey. 
Participants remained in the same cohort, in a staggered start-up arrangement. To ensure each 
participant will receive 8-weeks of MHA usage, the final participant was enrolled by October 30, 
2019. Participants may stop using the MHA at any time without recourse. Those who did not 
complete at least 1 week of usage will be excluded from statistical evaluation. The plan is to 
enroll 25 participants in the launch of this pilot EBP project, in hopes to have 20 participants 
complete the 8-week program. 
The final meeting included a satisfaction survey (See Appendix G) related to the 
enrollment into the MHA program and a post-intervention Self-Care Revised-Inventory tool, 
which was completed by December 31, 2019. The satisfaction survey provides significant 
information about positive and negative experiences of the MHA program. These reported 
experiences are critical when developing a protocol that is patient-centered and individualized. 
Satisfaction surveying opens a dialogue with patients and lets them know providers are 
listening, identifies issues with intervention, and recognizes opportunity to make improvements 
and be more efficient (Coville, 2011). The Self-Care Revised-Inventory tool is specific to 
diabetes mellitus (DM). Post-intervention assessments in comparison to pre-intervention 
assessments will help determine if the MHA program improves self-care perception. 
Researchers found that MHA’s lead to improvements in patient satisfaction, a stronger 
perception of self-care practices, and satisfaction with treatment suggesting this type of 
technology may be an effective strategy for changing patient self-care behaviors (Bonoto et al., 
2017). 
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Protection of Human Subjects  
 Protection of human subjects is of high priority with any type of research or EBP project. 
According to the Belmont Report of 1979, scientific research has produced social benefits as 
well as some troublesome ethical practices (Beauchamp, 2008). From this report three 
principals have been found to be most relevant to research involving human subjects. Those 
principles include respect for the person in which that individual should be treated as an 
autonomous agent and protection allotted for those with diminished autonomy (Beauchamp, 
2008). A second principle is beneficence and is understood as the kindness that goes beyond 
stand obligation to a person, in which the research shall maximize benefits, and do no harm to 
the human subjects. The final principle is justice and is understood as a sense of distributed 
fairness in which each person has an equal share according to individual need, individual effort, 
each person’s societal contribution, and to each person according to merit (Beauchamp, 2008). 
The DNP student for this project completed a certification program by the National Institutes of 
Health (NIH) for the protection of human research participants. Additionally, a class on ethics 
was completed to solidify the significance of ethical interactions with human participants.  
 Anonymity was maintained through use of an ordinal number coding system (See 
Appendix K) as the participants consented to join the EBP project. They were instructed to keep 
their number confidential and only identify themselves by that number. The participant names 
and associated numbers were documented and kept confidential in a locked cabinet at the DNP 
student’s office. The number identification process would also be utilized by the DNP student or 
designee during check point follow-ups to maintain anonymity. Compliance tracking tools and 
excel spreadsheets will only reflect the code number of each corresponding participant in the 
project. Participants were given full disclosure at the initial meeting and the ability for them to 
consent and emphasizing the ability to withdraw from the MHA program for any reason. This 
particular project allows patients to continue with MHA usage even in the event they want to 
withdraw from the project without cost or penalty. Participants that agreed to partake in the 
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project did not receive any money or coercion tactics; joining was completely voluntary. An 
exempt review application was pursued and approved by the Institutional Review Board at 
Valparaiso University for this project.  
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CHAPTER 4 
FINDINGS 
To determine the effects of a MHA on adults with uncontrolled T2DM in the primary care 
setting statistical testing was completed to analyze the impact on HbA1C, SCP, and SCB. SPSS 
22 was used to perform paired sample t tests to compare the primary outcome measure of pre- 
and post-intervention HbA1Cs. Two secondary outcome measures were also analyzed in this 
EBP project. A paired sample t test was used to compare pre- and post-intervention SCP, and a 
Wilcoxon Matched Pairs analysis was performed on this data to determine the effect of a MHA 
on participant perception on SCB activities.  
Participants 
A retrospective chart audit produced 150 potential participants who met inclusion criteria 
for the project. The project leader made telephone contact with 40 individuals who met inclusion 
criteria. Twenty-five participants agreed to participate the Living Sweet pilot program of which 18 
completed the program. The seven that did not start the program, complete the final HbA1C, 
complete the final SCI-R, or satisfaction survey were excluded from statistical analysis (See 
Figure 4.1). Pre- and post-intervention characteristics were identical as discussed in Chapter 3, 
and the statistical analysis used was selected based on a within group design. Those who 
participated in the intervention were reflective of the adult uncontrolled T2DM population within 
the organization. Eighteen patients, five men and 13 women with a mean age of 52.2 years (SD 
= 8.02, range 43-71), completed the Living Sweet MHA program. All participants were 
Caucasian. Their mean duration with T2DM was 12.7 years (SD = 7.9, range 0.5-31) (See 
Table 4.1). All of the advanced practices nurses of the organizational completed referrals to the 
Living Sweet MHA program, and the physicians did not participate.  
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Figure 4.1. Participant Recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potential participants from 
chart audit 
N= 150 
Phone contact for initial 
check point meeting 
N= 40 
Declined 
participation in 
program 
N = 14 
Agreed to participate and 
started the program 
N = 25 
Completed 
program 
N=18 
Did not  
complete program 
N=7 
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Table 4.1   
Participant Demographic Data  
Characteristic                   Frequencies/Results 
N =                18.0 
Age, mean, (SD), range                 52.1 (8.02), 43-71 
Sex, women/men                13/5 
Years with T2DM, mean, (SD), range                12.7 (7.9), 0.5-31 
Weeks of data input, mean, (SD), range                  6.7 (2.0), 3-8           
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Changes in Primary Outcomes 
 The effects of a MHA on glycemic control was evaluated using the statistical test of 
paired sample t test to determine the difference between the pre- and post- intervention 
outcome measure of HbA1C. Paired t tests are used to make comparisons of within group 
designs at two different points in time (Cronk, 2018). Pre-intervention data were collected 
through a retrospective chart audit of all adults with T2DM, and those with HbA1C of greater 
than 8.0 who met inclusion criteria were invited to participate. Phone contact was made to each 
qualified participant to inquire about joining the EBP project, and those that agreed attended an 
initial check point meeting describing the program details and responsibilities. During an 8-week 
period, participants recorded SCB outcome measures daily into the MHA. This data included 
glucose monitoring results, activity engagement efforts, and medication adherence efforts that 
each participant completed. The project leader received the data through the export function of 
the MHA. Exported data would be reviewed by the project leader, and at that time it would 
determine if participants met or did not meet the goals that they had set for themselves at the 
initial start-up meeting. Participants were expected to meet their self-determined goal 100% in 
order for the SCB to be considered met. Nurse practitioners also received exported data from 
the project leader to keep them informed of their patient progress in the program. At the 8-week 
final check point meeting a post-intervention HbA1C, SCI-R and a satisfaction survey was 
completed.  
Glycemic Efficacy 
 The measures of glycemic efficacy, obtained from retrospective chart audits of pre-
intervention HbA1C (M = 9.95, SD = 1.07) and post-intervention HbA1c results (M = 8.20, SD = 
1.10) were evaluated using paired t tests. The decrease in the HbA1C was found to be 
statistically and clinically significant (t = 6.674, df = 17, *p <.05). See figure 4.2 
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Figure 4.2. Glycemic Efficacy  
 
Pre- Intervention: M = 9.95, SD = 1.07 
Post- Intervention: M = 8.20, SD = 1.10 
t = 6.674, df = 17, *p <.05 
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Changes in Secondary Outcomes 
 Two secondary outcomes were analyzed. Evaluating the effects of the MHA on SCP and 
SCBs were secondary purposes of this EBP project. Patient satisfaction was an outcome of 
interest because utilizing a MHA that produced dissatisfaction would be counterproductive to the 
improvement of SCP and SCB.  
Self-Care Perception 
 A SCI-R survey was completed at the initial and final check point meeting for each 
participant who completed the program (N = 18). This tool was reported within the literature as 
being valid and reliable (Weinger, Welch, Butler, & La Greca, 2005). Reliability testing was 
completed using Cronbach’s Alpha analysis, which found the tool reliable (.796). Validity testing 
was also completed using a 1-tailed Pearson’s Correlation Coefficient. Pre-intervention SCI-R 
indicated significant validity of the tool (.683, p = .001) as did post- intervention validity testing 
(.683, p = .001).The survey scores were totaled and a paired t test analysis was completed on 
pre-intervention scores (M = 34.6, SD = 10.5) and post-intervention scores (M = 42.6, SD = 
8.09). The findings indicated that there was a statistical and clinical significance in SCP (t = -
4.403, df  = 17,  *p  < .05) (See figure 4.3) Pre- and post- intervention SCP comparisons were 
also made of the behaviors that were the focus of this EBP project. This included personal 
perception of checking glucose, recording glucose, activity engagement, and medication 
adherence (See figures 4.4, 4.5, 4.6, 4.7).  
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Figure 4.3 Total Self-Care Perception 
 
Pre- Intervention: M = 34.6, SD = 10.5 
Post- Intervention: M = 42.6, SD = 8.09). 
t = -4.403, df  = 17,  *p  < .05 
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Self-Care Behaviors 
 Participants recorded behaviors of medication adherence, glucose monitoring, and 
activity engagement according to the personal goals set by each participant. Over the course of 
the 8-week program, behaviors entered into the MHA across all three domains. Frequency 
analysis was completed to determine adherence to the use of the MHA, and expressed as 
percentages. Across all three domains the highest frequencies were at week 1 and week 2 for 
glucose monitoring ( 72.2%, 72.2%) and medication adherence (88.9% and 94.4%). Glucose 
monitoring declined by week 8 (55.6%) as did medication adherence at week 8 (72.2%). Activity 
engagement was highest at week 1 (72.2%), and declined significantly by week 8 (38.9%) (See 
Figure 4.4). Behaviors monitored throughout the 8-week period were important to evaluate 
program adherence of participants while using the MHA, but statistical analysis were not able to 
be performed due to lack of pre-intervention behavior assessment for comparison. However, 
pre- and post- intervention SCP comparisons were made of the behaviors that were included in  
this EBP project. Behaviors included participant perception of glucose checking, recording the 
glucose result into the MHA, medication adherence, and activity engagement, and results were 
drawn from pre- and post- intervention SCI-R surveys (See figures 4.5, 4.6, 4.7, 4.8). A 
Wilcoxon test examined the results of pre- intervention and post- intervention of checking 
glucose. A significant difference was found in the results (Z = 2.389, *p < .05). Post- intervention 
results were significantly better than pre- intervention results. A Wilcoxon test examined the 
recording of glucose results pre- intervention and post- intervention. A significant difference was 
found in the results (Z = 2.666, *p < .05). Post- intervention results were significantly better than 
pre- intervention results. A Wilcoxon test examined pre- and post- intervention of participant 
adherence to their prescribed medications specific to the treatment of their T2DM. A significant 
difference was found in the results (Z = 2.313, *p < .05). Post- intervention results were 
significantly better than pre- intervention results. A Wilcoxon test examined pre- and post- 
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intervention of engagement of activity. A significant difference was not found in the results (Z = 
1.718, p > .05). Post- intervention results were not better than pre- intervention results.  
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Figure 4.4. MHA Recorded Self-Care Behaviors 
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Figure 4.5 Perception of Checking Glucose  
 
(Z = 2.389, *p < .05) 
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Figure 4.6 Perception of Recording Glucose  
 
(Z = 2.666, *p < .05) 
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Figure 4.7  Medication Adherence Perception of Medication Adherence 
 
(Z = 2.313, *p < .05) 
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Figure 4.8 Perception of Activity Engagement  
 
(Z = 1.718, p > .05) 
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Participant Satisfaction 
A Likert-scaled satisfaction survey was created that focused on the MHA used for this 
project (MySugr®). Individual scores for each category on the satisfaction survey determined that 
participants were satisfied with the use of the MHA (See Table 4.2). Participants rated a relatively 
high score for cumulative satisfaction for the use of a MHA (M = 31.94, SD = 3.81). High score 
for the survey was 35. (See Table 4.2). 
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Table 4.2   
Participant Satisfaction  
Category                              Range                         Mean                          SD 
Download Application  3, 5    4.6          0.70 
Use of Application  4, 5     4.7          0.49 
Exporting Data  3, 5    4.6          0.70 
Track Glucose     4, 5    4.7          0.49 
Track Activity    3, 5    4.6          0.70 
Track Medication  4, 5     4.7          0.49 
Overall Satisfaction  4, 5    4.7          0.49 
Cumulative Score           22, 35                          31.94                        3.81 
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Conclusion 
In summary, statistically and clinically significant results were found with use of a MHA 
regarding the effect on HbA1C and SCP. Interestingly, there was a notable inverse relationship 
between HbA1C and SCP. When SCP was at the lowest point, HbA1C was at the highest, and 
when SCP was at the highest point, HbA1C was at the lowest point. There was a statistically 
significant difference for participant SCB perceptions for checking glucose, recording glucose, 
and medication adherence. However, activity engagement was not found to be significantly 
different. Satisfaction scores were high, and according to survey results participants’ expressed 
liking the application’s overall functionality and ease of use.  
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CHAPTER 5 
DISCUSSION 
The EBP project was completed to examine the clinical research question: What is the 
best practice for adult T2DM patients to achieve glycemic control and improve self-care 
behaviors. Additionally, the clinical question addressed the impact of a MHA on self-care 
perception. This project was posed to identify what intervention has been found, through best 
evidence, to achieve glycemic control in adult T2DM patients, thereby lessening debilitating 
complications related to chronically elevated HbA1C levels. High level literature supports the 
use of mobile-phone technology to improve glycemic outcomes for those adults with 
uncontrolled T2DM. The goal of this EBP project was to implement an intervention that utilized a 
multi-functional MHA to encourage self-care behaviors of glucose monitoring, activity 
engagement, and medication adherence. This chapter will explore the project findings, describe 
the benefits of the selected EBP framework, strengths and weaknesses, and implications for the 
future.      
Explanation of Findings 
 The PICOT question for this project asked: “In adult T2DM patients with HbA1C values 
higher than 8.0 in a  primary healthcare setting (P) what is the effect of a mobile-phone diabetes 
support application (I) compared to traditional diabetes education (C) on HbA1C results, self-
care behaviors, and self-care perception (O), over an 8-week period (T)?” The findings will 
reflect the answers to the burning question that was the impetus for this EBP project. 
 Initially, a total of 40 participants were selected for this EBP project, 25 of which agreed 
to participate. Of the 25 participants, 18 completed the program and eight of them did not start 
or did not complete the final check point evaluation at week eight making the completion rate 
72%. Completing the final check point was critical to the project evaluation because at that point 
post-intervention data was collected for comparison purposes. This data collection included 
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post-intervention collection of a HbA1C, SCI-R survey, assessment of behaviors recorded by 
the participant, and a satisfaction survey.   
Glycated Hemoglobin 
 After 8-weeks of the intervention, the final HbA1C, SCI-R, SCB, and satisfaction surveys 
were recorded by the project leader. The primary outcome measure was to determine the 
difference between pre- and post- intervention HbA1C results. A statistical analysis was 
performed using a Correlated t test, and the findings resulted in a statistically and clinically 
significant improvement (t = 6.674, df = 17, *p <.05) in the reduction of HbA1C. The data 
revealed a mean reduction of HbA1C of the post-intervention results (M = 8.20, SD = 1.10) 
compared to the pre-intervention results (M = 9.95, SD = 1.07). The mean reduction in HbA1C 
was 1.75%. This finding was higher than what was found in some of the literature (Hou, Carter, 
Hewitt, Francisa, and Mayor, 2016; Pal et al., 2014; Wang, Xue, Huang, Huang, and Zhang, 
2017), and in some pieces of literature the findings were similar (Fu, McMahon, Gross, Adam, 
and Wyman, 2017; Wu, et al., 2017. The higher reduction in HbA1C may be attributed to the 
Hawthorne effect that is frequently associated with people when they know their performance is 
being closely monitored (Kenton, 2019). According to the integrative review by researchers Fu, 
McMahon, Gross, Adam, and Wyman (2017), HbA1C was reduced 0.15-1.9% from baseline, 
and statistical significance was found in studies in which MHAs were multi-functional and 
interactive. A systematic review by Wang, Xue, Huang, Huang, and Zhang (2017), found that 
the use of MHA technology resulted in a decreased HbA1C of 1.0 %. Researchers of another 
systematic review found that the MHA-based intervention was associated with HbA1C 
reductions of 0.66% - 1.96% (Wu, et al., 2017). Pal et al. (2014) found a modest HbA1C 
reduction of 0.50% with use of a MHA, and Hou, Carter, Hewitt, Francisa, and Mayor (2016) 
found a mean HbA1C reduction of 0.41%.    
 
 
Mobile Application to Improve Glycemic Outcome                                                             71 
 
 
Self-Care Perception 
 Uncontrolled T2DM places the individual at risk for severe complications and complex 
comorbid conditions including, heart disease, stroke, renal disease, vascular disease, 
neuropathy, amputations, and death (ADA, 2018). T2DM is a chronic disease that demands 
daily assessment and care by those afflicted with the disease. The daunting task of self-care 
management for this chronic disease is challenging and overwhelming in many cases (Vermeire 
et al., 2005). For this reason, SCP was evaluated in this EBP project to determine the impact of 
the MHA. SCP is one’s belief people can care for themselves, and the use of MHAs seems to 
strengthen perception of self-care by contributing better information and health education to 
participants (Bonoto, et al., 2017). The higher the SCP score the better one believes they can 
care for themselves. The tool used to assess SCP was the SCI-R self-report survey. This tool 
was found to be reliable and valid in the literature (Weinger, Welch, Butler, & La Greca, 2005) 
and through statistical testing. A Correlated t test was calculated to compare the mean pre-
intervention SCP to the mean post- intervention for the 8-week intervention. A statistically 
significant increase in SCP results were found post- intervention (M = 42.6, SD = 8.09) 
compared to pre- intervention (M = 34.6, SD = 10.5) (t = -4.403, df  = 17,  *p  < .05). For 
comparison purposes, pre- and post- intervention data specific to the SCP of checking glucose, 
recording glucose, activity engagement, and medication adherence were analyzed (Figures 4.5, 
4.6, 4.7, 4.8). This comparison was not reported individually within the literature, however the 
changes between pre- and post-intervention perceptions in these areas illustrates how SCP was 
impacted through the use of a multi-functional MHA. The improvement in SCP with the use of a 
MHA was similar to the results found within the literature. A systematic review found the use of 
MHA seemed to improve SCP by increasing information and health education of 
patients.(Bonoto, et al., 2017). Clement et al. (2018) suggested that technology such as MHAs 
increased patient satisfaction and knowledge improving self-management perceptions. The 
findings provide evidence that using a MHA improves SCP and suggests participants feel more 
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confident when preforming self-care activities for the management of their uncontrolled T2DM. 
For the purpose of this project, analysis of specific behaviors related to this project within the 
SCI-R tool were completed to compare self-reported pre- and post- intervention results (see 
figures 4.5, 4.6, 4.7, 4.8).  
Self-Care Behaviors 
 SCBs for this project were glucose monitoring/recording, activity engagement, and 
medication adherence. These are three of the self-care management behavior domains 
recommended by the ADA that lead to the reduction of HbA1C (ADA, 2018). A frequency 
analysis for each week was completed on each behavior to determine participant adherence to 
the use of the MHA. Initial percentages were high with a steady decline that occurred over the 
course of the 8-week period (see figure 4.4). This may be have been due to the lack of 
evaluating participant recorded SCB practices prior to the initiation of the MHA. Evaluating this 
prior to starting the MHA may have demonstrated a more  accurate representation of 
participation patterns. This should be a consideration for future  EBP projects  and 
organizational outcome measures that focus on evaluating SCB practices related to the use of a 
MHA. One week after participants used the MySugr® MHA, recorded behaviors were reviewed.  
High completion percentages which were most likely due to the Hawthorn effect. This 
phenomenon occurs when people feel their performance is being monitored, thus causing an 
excessively high performance of activity or completion of duties (Kenton, 2019). Weeks 2-4 
showed a decrease in SCB’s, between week-5 and week-6 there was a slight increase in the 
percentage of successfully met behavior goals. This was most likely due to staggered start 
process in which all participants completed the 8-week program but joined and finished at 
different points in time. Participants who joined during the initial participants’ weeks 5 and 6 
were also subject to the Hawthorn effect. During this particular timeframe, seven new 
participants joined the program, and I believe this relates to the spike in SCB adherence.  
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Analysis of specific behaviors related to this project within the SCI-R tool were 
completed to compare self-reported pre- and post- intervention results (see figures 4.5, 4.6, 4.7, 
4.8). There was a statistically significant improvement in the perception of SCBs for checking 
glucose, recording glucose, and medication adherence when comparing pre- and post- 
intervention results. There was not a statistically significant difference in perception of activity 
engagement between pre- and post- intervention data. According to Bonoto et al., (2017), 
participants reported that they felt like they engaged in these key behaviors and when 
preformed consistently led to improvements in glycemic control and patient outcomes.  
Literature supported the use of MHA’s to enhance SCB practice for adults with T2DM (Bonoto et 
al., 2017; Clement et. al., 2018;; Mann, 2018; Nguyen, 2018; Pamaiahgari, 2018). Findings in in 
the literature indicated that integration of a MHA for the self-management of T2DM may result in 
reductions of HbA1C and glycemic and cardiovascular risk factors (Clement et. al., 2018). Self-
monitoring of glucose is a main strategy to attain glycemic control, which is a main component 
of MHA’s. Thus, MHA’s encourage SCBs that result in reductions in HbA1C which emphasizes 
the importance of using this technology in the primary healthcare setting (Bonoto et al., 2017). 
The literature used in this project identified 11 different MHAs that were used by the intervention 
groups. Application features included health data storage, positive feedback parameters, and 
motivational feedback for glucose, activity, and medication recording, all of which were present 
in the MySugr® MHA. All of these features were found to contribute to glycemic control (Fu, 
McMahon, Gross, Adam, & Wyman, 2017; Hou, Carter, Hewitt, Francisa, & Mayor, 2016; Wu et 
al., 2017; ). Subgroup analysis determined that MHAs with features such as positive feedback 
and glucose, activity, and medication recording generated better and statistically significant 
improvements in HbA1C (Bonoto et al., 2017). A clinical practice guideline (Clement et al., 
2018) did not report individual SCBs as an outcome,  but noted that the MHAs with the features 
mentioned above improved SCB adherence, improved access to health care professionals, and 
contributed to better glycemic control. A systematic review indicated that MHA engagement 
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decreased over time, however statistically significant reductions in HbA1C were achieved 
(Bonoto et al., 2017). It was noted that reductions in HbA1C may have been due to factors 
unrelated to the MHA, such as increased knowledge regarding the implementation of the MHA 
platform to record and encourage behaviors related to reducing HbA1C. This reinforced 
knowledge  about behavior changes that lead to improved HbA1C, which may have caused 
improvements in self-care changes leading to improved HbA1C. Interestingly these researchers 
found generally high participant engagement for all components of the MHA the first week and 
then decreased engagement progressively overtime consistent with the behavior pattern 
observed in this EBP project. Additionally, they found that blood glucose monitoring had a 
statistically significant improvement while activity engagement did not (Bonoto et al., 2017). 
These findings were similar to the findings of this EBP project,  (Bonoto et al., 2017). Best 
practice recommendations include MHA-based support programs for the management of 
diabetic patients (Pamaiahgari, 2018), and structured self-monitoring of blood glucose was 
found to be more beneficial than non-structured self-monitoring of blood glucose testing in 
reducing HbA1C (Nguyen, 2018). Structured self-monitoring means that glucose checks are not 
only encouraged but a technologically platform is provided to record, store, and export self-
monitored blood sugars. A systematic review by Hou, Carter, Hewitt, Francisa, and Mayor 
(2016) promoted MHAs to improve patient self-management with the enhanced ability to 
monitor blood glucose, physical activity, and medication adherence.  
Participant Satisfaction 
 Participant satisfaction was also evaluated because this is an important aspect when 
selecting a MHA as patients desire one that is considered easy to use and understand (Fu, 
McMahon, Gross, Adam, & Wyman, 2017). Researchers suggest that MHAs that are user 
friendly and multi-functional are best for improving SCB’s that lead to improved glycemic control 
(Fu, McMahon, Gross, Adam, & Wyman, (2017).  
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Cumulative patient satisfaction results for the use of a MHA in this project reflect high 
satisfaction (M = 31.94, SD = 3.81) with a range of 22,35. Individual satisfaction domains 
specific to the focus of this EBP project included tracking glucose, activity, and medication 
adherence and recording. Interestingly, tracking glucose and inputting data onto the MHA were 
ranked the top two domains in satisfaction. This may be due to the user-friendly aspects of the 
device, and to the positive reinforcement in real-time elicited by the application when data was 
entered. MySugr® has a “sugar monster” on the application and he smiles and giggles or frowns 
and scowls accordingly to normal or abnormal blood sugars. The “sugar monster” also turns 
colors based on the blood sugar number entered with green signifying a normal range, yellow 
approaching out of range, and red representing a result that was out of range. This was a 
unique positive reinforcement system and immediate feedback system specific to this MHA. 
Tracking activity and medications had lower satisfaction ratings, but only by a slim margin. The 
“sugar monster” would consistently be green, smile and giggle anytime activity and medications 
were entered into the MHA. Again, this provided consistent positive reinforcement in real-time.  
Literature suggests that MHA use increased patient satisfaction of self-care management 
behaviors by enhancing knowledge and promoting improvement in quality of life and self-
confidence to manage T2DM (Bonoto et al., 2017; Clement et al., 2018). The heightened SCB 
practices, self-confidence, and self-care knowledge fosters improvements in HbA1C and 
decreased risk of complex comorbid complications.  
Strengths and Limitations of the DNP Project 
EBP Model  
 The EBP framework used to guide this EBP project was the Iowa model of evidence-
based practice to promote quality care. The Iowa model provided a conceptual framework for 
the selection and development of this EBP project. It consists of seven steps: selection of a 
topic, forming a team, evidence retrieval, grading the evidence, developing an EBP standard, 
implementing the EBP standard, and evaluation (Titler et al., 2001). Step I was the selection of 
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a topic which included the task of identifying an organizational quality measure that was falling 
below metric standards set forth by key reimbursement agencies such as CMS. Included in this 
selection process was the consideration of current policy, organizational mission, and key 
stakeholder influence that may produce limitations for the project. It was found that in quarter-
one of 2019 that 59.3% of diabetics within the primary care organization had HbA1C results of 
greater than 9.0, while quarter-two indicated that 66% had HbA1C greater than 9.0. These are 
considered poor quality measure outcomes and are well above the expected national standard 
of 45% or less of adults with diabetes mellitus having a HbA1C of less than 9.0 (CMS, 2017). 
Uncontrolled diabetes mellitus is directly linked to complex conditions and complications that 
include: Cardiovascular disease, stroke, diabetic ketoacidosis, kidney disease. eye disease, and 
amputation of a lower extremity (CDC, 2017).The use of a MHA to encourage adults with 
uncontrolled T2DM to improve completion of self-care behaviors ultimately leading to improved 
HbA1C results. Reducing HbA1C was a priority for the stakeholders of this organization, i.e.,  
physicians, nurse practitioners, quality management, risk management, and senior leadership. 
The idea of using a MHA in the primary care setting did not take hold as the project leader 
expected it would. Several meetings and presentations occurred with individuals and groups of 
stakeholders to promote the EBP project. Support for the project development was mainly 
provided from quality and risk management leaders, while nurse practitioners heavily supported 
the implementation process. Physicians did not want to engage in any of the development, 
implementation or evaluation phases due to the time involved. One physician voiced opposition 
of adding a MHA as a primary care provider-driven tool, due to time constraints and how this 
may negatively impact quarterly revenue bonuses. The original protocol was primary care 
provider-driven, but senior leadership thought it would be better utilized as a nursing 
intervention standard in the diabetes education program that was needing serious revisions. It is 
now recognized that the diabetes outcome metric is not being met within the organization, and 
loss of reimbursement by CMS is at risk. The Chief Nursing Officer (CNO) recommended use of 
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the MHA as an evidence-based tool for the management of adults with uncontrolled T2DM, and 
to improve outcomes for the organization. The project is now being integrated into the diabetic 
chronic care management and transitional care management programs of the organization. The 
protocol will need to be reviewed by medical staff for approval and modifications will occur as 
recommended. Modifications may include setting different target ranges for blood glucose 
results and blood glucose monitoring intervals for those on insulin and those who do not use 
insulin. These target ranges would need to be determined by the patient care review committee 
as a guide to the diabetes care team.  
 Step II is the engagement of a team that will be responsible for the development, 
implementation, and evaluation of the project. The makeup of the team is driven by the chosen 
topic and include associated stakeholders (Titler, 2001). The project leader determined that a 
small interdisciplinary team would be best for the development of this EBP project. The 
organization is considerably small and generally functions on a more intimate level of 
communication. The team included the project leader, project preceptor/quality manager, and 
the risk manager. It was impressive to see the level of attention that was given to the project by 
the project preceptor/quality manager and the risk manager. The project preceptor/quality 
manager was involved in the development and workflow of initiating the MHA. She came to the 
office of the project leader on a few occasions to discuss the literature findings, protocol 
development, and recruitment efforts. Additionally, she integrated the program into the EMR to 
streamline the referral process for the nurse practitioners. The risk manager reviewed the IRB 
from Valparaiso University, all of the forms that were created for the project, and the focus of the 
project. The project leader was impressed with the enthusiasm of these team members and 
appreciated the recommendations from these leaders. The nurse practitioners were considered 
the key stakeholders due to the probability that the majority of the referrals would be coming 
from them. Two of the nurse practitioners who originally said they would start participants on the 
program did not do so. The project leader ended up meeting with all 26 of the potential 
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candidates and then followed the 18 participants for 8 weeks without participation of the other 
two nurse practitioners. Their assistance may have increased the number of participants that 
joined the program. The physicians showed extreme resistance to the project, and the project 
leader’s collaborating physician stated he did not want to take the time to start a patient on the 
MHA. He indicated from the start that the MHA may have a place in the organization, but should 
not be physician or nurse practitioner driven. The project leaders does not agree with this and 
believes the use of the MHA to reduce HbA1C should remain a primary care provider-driven 
practice guideline as nurses cannot make medication adjustments that are often needed to 
improve glycemic control. Activity adjustments and glucose monitoring would also need to come 
from the primary care providers. Advanced practice nurses are well suited to make these 
adjustments based on exported data and improve outcome measures while reducing risk of 
secondary complications. The project leader did not receive any referrals from a physician. 
However, the project leader was able to speak to some of the physicians’ patients, and they 
agreed to join the program. The physicians did not resist their patients being in the program and 
accepted the exported data by email from the project leader without issues. When a participant 
joined the program, their provider was made aware of their patient’s informed decision and 
instructed to expected exported data in their email weekly. This information kept them prepared 
and helped them understand what to expect from the project leader.  
 Step III entails evidence retrieval. Brainstorming amongst the members should be held 
to identify available resources to guide the search for evidence (Titler et al., 2001). Once the 
priority was established, the quality and risk leader team members assisted in the development 
of the EBP project. The project leader retrieved and evaluated the level and quality of the 
evidence and explained it to the quality and risk team members. This was a lengthy and 
exhausting process, but necessary to assist the other team members’ full understanding of what 
EBP entails. Much of the discussion focused on the project implementation process and 
retrospective chart review. The quality leader was able to pull the names of the patients with 
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T2DM that had HbA1C greater than 8.0, which was essential to evaluate the full scope of the 
problem within the organization. The risk leader was essential in making sure the written forms 
for the project were clear and did not put the hospital at risk or litigation. The project leader’s 
main role was to ensure the evidence was at the highest level and quality available and to keep 
the other team members informed of the findings.   
 Step IV is the process of gathering, critiquing and synthesizing pertinent research related 
to the desired practice change (Titler et al., 2001). In this case, the project leader was required 
to appraise the strength and quality of the evidence that was found as a result of an exhaustive 
literature search. Through this search it was determined that there was an large amount of high 
evidence available to support change in practice. Evidence was leveled through Melnyk and 
Fineout-Overholt’s Hierarchy of Evidence ( Melnyk & Fineout-Overholt, 2015). Critical appraisal 
of the evidence was completed through use of the CASP tool (CASP, 2017), and the AGREE II 
tool for clinical practice guidelines (Brouwers et al., 2010). 
STEP V is the development of a new practice based on a patient-centered evidence-
based practice standard that is highly individualized. Once the literature is critiqued, team 
members develop a set of recommendations that guide the new practice (Titler et al., 2001). 
The project leader created an individualized patient-centered EBP protocol/ practice standard 
for the organization that was revised continually throughout the implementation process as 
barriers were encountered. The first barrier was experienced as the new practice standard was 
introduced to the organization came with a significant barrier. The Living Sweet MHA program 
was recommended to be initiated as a nursing intervention, but because nurses cannot adjust 
medications, glucose testing intervals, or activity recommendations at this organization, the 
primary care providers had to manage these aspects of the program. This meant the practice 
change would need to go through the patient care review committee before it could be added to 
the approved diabetes education regimen. The patient care review committee is comprised of 
only physicians. This barrier will be addressed through a presentation at a future patient care 
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review committee meeting. Additionally, selecting a MHA for this project also became a 
challenge due to the abundant options to choose from. The project leader sampled and 
reviewed roughly ten applications before selecting MySugr®. This particular MHA was free to 
use, was multi-functional and included the ability to document all three behaviors being 
monitored in the EBP project, was very user-friendly, came with a color-coding system to help 
the user determine if the blood sugar was in good range (green), moderate range (yellow), or 
poor range (red).  
The start-up meeting consisted of a complete in depth instructional in-service for each 
participant with emphasis on the use of the MHA, selecting personal goals for each behavior, 
and specific project leader and participant responsibilities. Weekly check points were used as a  
teaching moments to reinforce the proper use of the MHA, self- selected behavior goals, and to 
clarify any concern or question a participant had regarding the MHA. The new practice standard 
protocol was reviewed after implementation by all team members, and it was suggested that it is 
more relevant and feasible as a nursing intervention for the diabetes education program rather 
than a provider-driven practice protocol. This means that when a primary care provider sends a 
referral to the diabetic education team, they will utilize the MHA protocol as an additional tool to 
promote glycemic efficacy. The reason behind the creation of the EBP protocol is to improve the 
quality and consistency of diabetic education throughout the organization. This was suggested 
by senior leadership and eliminated a significant barrier that was resistance from medical staff 
members. The protocol will still need to be approved by medical staff, which is made up of 
physicians, but will likely be accepted as an evidenced-based tool for improved diabetic care 
glycemic outcomes. The primary care providers’, including nurse practitioners’, role will be to 
medically manage medication types and dosages, activity engagement, and glucose monitoring 
intervals based on the exported data they receive from the patients that are using the MHA. 
Once the medical staffs approves the integration of the MHA into the diabetes education 
program, the nurses will start participants on the program and track their progress. Diabetes 
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nursing staff will forward export data to primary care providers when exported data results are 
consistently falling out of target ranges. The significance of this is the sooner the nurse 
practitioner makes adjustments, the sooner the patient will reach glycemic control.    
Step VI is the implementation of the new EBP standard which begins with written 
policies, procedures, and guidelines. Policy development requires direct interaction between the 
team members, direct care providers, and organizational leaders to support the practice change 
(Titler et al., 2001). The protocol was developed and implemented with continual revisions to 
meet limitations and barriers that were encountered throughout the launch of the Living Sweet 
program. Revisions included adding a prompt within the protocol for the designated staff 
implementing the MHA to contact the patient before the initial meeting to request their phones 
are updated with the most current operating system. Another revision added was a prompt to 
request patients know the email and password that corresponds to the application store on their 
smart phone. Also, the protocol was changed from a provider-driven tool to a nursing 
intervention for the improvement of diabetes outcome measures.  
Step VII is the evaluation step which is essential to seeing the value and contribution of 
applying the evidence to practice. Baseline comparison data prior to project implementation is 
beneficial to show how the new evidence-based practice has affected patient care (Titler, 2001). 
Data collection flowsheets were created to track the data for all outcome measures and group 
demographic characteristics. The project leader completed eight check-points for each 
participant (N = 18), and was available by phone for consultation regarding any concern or any 
trouble shooting issues related to the use of the MySugr® MHA. The time involved in preforming 
check-points depended specifically on the needs of the participants and how well they 
comprehended the MHA functions. Additional time was spend reinforcing the three SCBs that 
were being monitored and the steps for exportation of the data to the project leader. Initial check 
points lasted between 30-45 minutes and as the program progress the check points occurred 
over 10-20 minutes. Check points were integrated into the program to determine and address 
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barriers and limitations. This was helpful in revising the protocol to make it more streamlined 
and functional for those that were going to be providing education about the program to future 
patients. This approach was not intended to be sustainable long term as once participant and 
workflow issues were identified and resolved, the checkpoints would no longer be needed. In 
future practice, primary care providers could set exportation expectations for each patient that 
utilizes the MHA program. The project leader evaluated the outcome measure data using 
statistical tests with SPSS 22 software. 
Strengths 
 There were many strengths of this EBP project. The most profound strength was the 
collaborative efforts between advanced practice nurses, senior leadership, and quality and risk 
management departments. The support by key stakeholders had significant influence in the 
development, implementation, and evaluation processes of this EBP project. For instance, the 
quality leader volunteered an abundant amount of time to help determined the number of that 
adults with uncontrolled T2DM that were well above the HbA1C benchmark according to CMS 
guidelines. She also recommended that the best way to elicit provider referrals was through the 
established EMR. Making the referral process streamline and simple was clearly an attraction to 
the primary care nurse practitioners. Implementation was supported by risk leadership as she 
critiqued the data tracking forms, instructional forms, and educational forms to keep structure 
and consistency to the entire implementation process. The project leader was the member who 
created the forms, contacted patients, implemented the program, and evaluated the outcome 
measures of the EBP project. The literature used for this project added clarity and confidence 
which was found to be a significant strong point when grooming key stakeholders and clinical 
staff. For example, the high level and quality of literature found was explained and reviewed with 
the primary care providers at four different meetings. These meetings were geared to sparking 
interest, garnering support, and eliciting qualified participant referrals. The MySugr® basic 
application was free to use for all participants which is a huge strength in the rural health care 
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setting, not to mention the multi-function capabilities of the MHA to be used as an individualized 
patient-centered intervention. In the event MySugr® would become cost prohibitive, there are 
other free multi-functional applications with similar features and are user-friendly such as 
Glucose Buddy (Glucose Buddy, 2017).  
The MySugr® application allowed for simplistic data entry by simply tapping on the my 
sugar icon. The user was able to enter blood sugars manually or through blue tooth technology 
if their monitor was compatible. After the number was entered or uploaded from the glucometer 
the user would tap the green check mark to record the data. The name of each diabetes 
medication was pre-selected for each participant and by simply tapping on the medication and 
then the green check mark, the data were recorded. Activities were recorded in a similar 
fashion. The MHA had other functions available, but for the purpose of this project these three 
SCBs were the only ones utilized. The MHA estimated the HbA1C for each participant if they 
submitted six glucose results for the week. This feature was helpful as the number may have 
encouraged participants to improve food selections, increase activity, or adhere to medications 
based on the results produced from current blood glucose results entered. An additional 
strength of the application is the participant was able to review seven days, 14 days, 30 days, 
and 90 days of data, and this included cumulative blood glucoses, physical activity engagement, 
and medication adherence at each data point. Furthermore, the MHA has no geographical 
barriers and promoted access to the healthcare provider through the exportation function. The 
opportunity to export real-time data was a significant advantage for those participants who did 
not have transportation to attend a traditional office visit. 
Limitations 
 The primary limitation was the small number of participants for the project (N = 18). 
Additionally, the project was short in duration and a longer time many have resulted in different 
outcomes for the primary and secondary objectives for this EBP project. Another limitation was 
that many of the participants engaged in the project over two major holidays in which there is an 
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abundant supply of nutritionally poor foods. People tend to increase consumption of sweets, eat 
larger portions of food, and increase alcohol consumption over holidays, all of  which can 
increase blood glucose and HbA1C. Regardless of the limitations faced in this EBP project, 
participants experienced a statistically and clinically significant decrease in HbA1C, improved 
SCP and SCB. The project lacked objective pre- intervention data regarding the SCB’s included 
in this project. A better approach may have been to collect SCBs from each participant prior to 
initiating the MHA, and compare them to post intervention SCBs that were recorded into the 
MHA. This would have reflected a more accurate representation of how SCBs were impacted by 
the use of the MHA. Finally, prospective participants that did not have a cell phone or tablet 
were unfortunately not able to participate in the project and were not able to benefit from the 
Living Sweet program. This specific limitation only was applicable to five of the participants that 
were originally contacted.  
 A participant related limitation was encountered early in the program. Internet connection 
was found to significantly impact the time involve when uploading the MHA to the smartphone 
and when inputting data. This did not cause a deterrent for the participants, but caused a barrier 
for the project leader. The first participant for this EBP project was started in the program in his 
home setting and it was extremely difficult to get the MHA downloaded onto his smartphone due 
to poor satellite connection and download speeds. The future recommendation is that 
participants start the program in the office setting with sound, consistent internet connections. 
The office setting in this organization has a broadband fast internet and uploading of the MHA 
took minutes versus hours with satellite internet services. Participants also seemed to have a 
difficult time remembering the email and password associated with uploading applications to 
their phones or tablets. The initial meeting with the first participant this was a significant issue. 
This limitation was addressed early during the initial phone call by the project leader by 
requesting that each participant have their email and password ready for the initial program 
start-up meeting. SCBs and SCPs were self-reported, which can be a limitation because self-
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reporting is subjective and may not have been accurately reported by the participants. Despite 
limitations related to self-reporting, SCBs, with the exception of activity engagement, and SCPs  
showed statistically significant improvements. 
Implications for the Future 
Practice 
 Improving HbA1C using a multi-functional diabetes specific MHA could be helpful in 
achieving glycemic efficacy, self-care perception, and self-care behaviors. The EBP project had 
a short duration of 8-weeks, but the MHA strategy demonstrated a statistically and clinically 
significant reduction in HbA1C and improvements in SCP and SCBs, with the exception of 
activity engagement. Regarding adherence to the use of the MHA, post- intervention recorded 
SCB activities declined over an 8-week period. Due to the suspected Hawthorne effect that 
frequently occurs during monitored projects, recorded activities may have been skewed during 
the initial weeks participants were using the MHA. Evaluating SCBs prior to the implementation 
of the MHA would have made a better reflection of the impact that the application had on 
recorded post- implementation SCBs. This was a flaw in the design of the project. Participants 
recording SCB practice data prior to the use of the MHA would have been a better comparison 
and provided more insight of how the application impacted SCBs. It is possible that even the 
lowest percentages of the post-intervention recorded SCBs could have been higher than pre-
intervention recorded percentages. This would have resulted in an increase in recorded SCB 
activities rather than the resulting decline that was found. Within the SCI-R tool, SCBs specific 
to this project were self-reported pre- and post- intervention by each participant, and those 
results were individually analyzed. Findings indicated that SCBs of checking glucose, recording 
glucose, and medication adherence demonstrated statistically significant outcomes. Activity 
engagement was not found to be statistically significant.  
Participants reported high satisfaction regarding the use of the MHA which is a bonus 
attribute that may lead to better adherence to a program geared at improving HbA1C. This EBP 
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project mean HbA1C result surpassed the primary outcome benchmark set by CMS of 9.0. This 
is clinically and statistically significant and suggests that providers should consider using the 
MHA to improve glycemic control in adults with uncontrolled T2DM in a primary care setting. 
Due to the lack of medical staff support it was suggested by senior leadership to transition the 
protocol into a nursing intervention. This was a significant suggestion, and the protocol was 
adopted by the organization as an additional tool to support adults with uncontrolled T2DM. At 
this time, the basic functions of the MySugr® MHA is free to anyone who would like to use it. 
Basic functions included recording of glucose, activity, medications, carbohydrates, weight, and 
HbA1C results.  The Iowa model used as a guide for the creation of this EBP project supports 
the team collaboration concept. This was clearly demonstrated by the collaborative healthcare 
team involved in the development, implementation, evaluation, and dissemination of the project. 
The importance of a team approach when establishing EBP protocol is due to the need for 
interdisciplinary engagement the new practice standard brings to the organization and brings 
other disciplines into the rollout process of the new practice standard. An example is the 
process of training the nurse-driven diabetes education team about the Living Sweet program. It 
is essential for these nurses to be well versed on how to download, use, and export data for the 
MySugr® application to an Android® or an iPhone® efficiently and effectively. Additionally, they 
will need to know how to change medication profiles and target blood sugar ranges as 
requested by primary care physicians, nurse practitioners, and physician assistants. The 
information technology leader was also brought into the project design portion. During the pilot 
the project leader received all of the EMR referrals, and this needed to know be delegated to the 
diabetic education team. Including the information technology leader in this project was 
essential to streamline the referral process to the appropriate people. The Iowa model has 
distinct team building attributes and that is why it was selected for this EBP project.  
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Theory 
 This project was guided by the Iowa model of evidence-based practice to promote 
quality care because of the team approach that is encouraged by the model to promote 
organizational change. The Iowa model guided the integration of the weekly check-point 
evaluations which encouraged continual revisions of the project until an efficient sustainable 
protocol was reached. Much like the Iowa model’s internal check and balance system, these 
check points were an internal evaluation of the project as it progressed. The model added clarity 
to the process and encouraged project leaders to assess and address barriers and limitations 
throughout the evaluation process. 
Research 
 Further research and education are needed to determine if reduction of HbA1C, SCP, 
and SCB improvements are sustainable using a diabetes-specific multi-functional MHA. The 
exportation of participant data to providers was instrumental to encourage accountability and 
positive impact on HbA1C, SCP, and SCB. An extended timeframe would be especially helpful 
in determining the impact on primary and secondary outcomes as well as participant 
engagement and attrition. Including a larger number of participants of different races, socio-
economic status, and different healthcare settings would help determine generalizability and 
feasibility. Recorded SCBs showed a decline over the 8-week implementation, however this was 
not a true reflection of  adherence to the use of the MHA because pre-intervention SCB analysis 
was not completed in this project. Evaluating pre- intervention recorded SCBs and comparing 
them to post- intervention recorded SCBs would have added more value and clarity to this data. 
Perceived SCBs showed an increase in over the 8-week implementation period, with the 
exception of activity engagement, which did not show improvement after the MHA was 
implemented. Also, an extended follow-up evaluation of six to 12 months of the HbA1C results, 
SCPs, and SCBs by the project leader may add merit and speak to sustainability of the use of a 
MHA for the self-management of adults with uncontrolled T2DM.  
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Education 
 Participant education was provided throughout this EBP project. The initial start-up 
meeting included printed material, and from that material dialogue was initiated by the project 
leader. Additionally, printed material was also created to guide the providers about the details 
and goals of the Living Sweet MHA program. This was designed to help them introduce the 
program to potential participants. The printed material included explanation of the referral 
process that was embedded in the electronic medical records. The material also informed 
providers that they would be receiving exported weekly data from their patients who decided to 
join the program. Prior to this EBP project the project leader and the other providers at the 
organization had not used smartphone applications to promote glycemic efficacy, SCPs, or 
SCBs. The nurse practitioners were key for educating their patients about the program and for 
initiating referrals through the electronic medical record and secured email system. They 
provided the project leader with warm referrals to the Living Sweet program and this allowed for 
a successful pilot. 
 Primary care physicians, nurse practitioners, and physician assistants have the 
responsibility to stay educated on technologic advancements that may empower individuals to 
not only manage their chronic disease, but to make improvements on outcome measures and 
prevent complex comorbid conditions. It is imperative they attend continuing education 
conferences and stay engaged in high level and high-quality literature.  
 
Conclusion 
 The findings of the EBP project determined that the diabetes-specific multi-functional 
MHA contributed to improving HbA1C, SCP, and SCB with the exception of activity engagement 
in the primary care setting. Moreover, use of a MHA for adults with uncontrolled T2DM is a 
feasible, sustainable, evidence-driven intervention that can contribute to diabetes self-care 
practices and prevention of comorbid conditions related to uncontrolled T2DM. This EBP project 
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used MySugr® smartphone application, but use of other MHAs are expected to reach similar 
outcomes to those found in this project. Other applications that are free of charge and multi-
functional similar to MySugr® are Glucose Buddy®, Diabetes Pal®, and Diabetes: M®.  
 Findings from the EBP project were congruent with those reported in the literature and 
answered the PICOT question : “In adult T2DM patients with HbA1C values higher than 8.0 in a 
primary healthcare setting (P) what is the effect of a mobile-phone diabetes support application 
(I) compared to traditional diabetes education (C) on HbA1C results, self-management 
behaviors, and self-care perception (O), over an 8-week period (T)? It was determined that the 
use of a MHA should be encouraged by primary care providers to promote glycemic efficacy,  
improve self-care perception, and promote self- care behaviors, such as glucose monitoring and 
recording and medication adherence, ultimately leading to a reduction in complex comorbid 
conditions. Nurse practitioners will monitor data exported by patients using the information to 
change medication regimens and dosages, activity recommendations, and glucose monitoring 
intervals to promote glycemic control and improve SCP and SCB practices. 
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Appendix A 
 
Clinical Protocol for the Living Sweet Program 
 
 
Living Sweet: 
    An Adult Type 2 DM 
Management Program 
PURPOSE: The is an evidence based project aimed at reducing 
glycated hemoglobin, while fostering self-care perception and self-care 
behaviors such as medication adherence, blood glucose monitoring, 
and physical activity engagement through the use of a diabetes-specific 
mobile smart phone application. 
INCLUSION CRITERIA: Participants must be 18 years or older, have 
type II diabetes, have the most recent HbA1C of greater than 8.0, and 
have access to a mobile smart phone. Pregnant women are not eligible 
to be in this program.   
 
• A referral is to be made through the secure electronic medical 
record to the designated program staff member.  
• The designated program staff member will confirm inclusion 
criteria, discuss participant guidelines, and provide hands-on and 
written instructions.  
• The designated program staff member and participant will 
determine personalized goals for blood glucose testing, physical 
activity, and medication administration (other self-care activities 
may be added upon request). 
• Participants will utilize the diabetes-specific mobile smart phone 
application to upload blood sugars, physical activity events, and 
medication administration events that are patient-driven and 
individualized.  
• Participants will send their uploaded results to the designated 
program staff member based on a pre-determined time not to 
exceed 2 weeks.  
• The designated program staff member will place reminder calls or 
texts in the event results are not received at the timeframe that 
was decided upon at initiation of the program. 
• Designated program staff member will review and communicate 
exported data to respective primary care providers. Providers will 
order specific medication regimens, activity goals, and glucose 
testing intervals. This will then be communicated to the patients by 
the designated staff member. 
 
 
  
 
 
 
Chantel Anderson  
MSN, FNP-BC 
Program Leader 
 
 
 
 
 
canderson@pmhnet.com 
219-863-9298 
 
 
 
 
-Melissa Jones 
Pulaski Memorial 
Hospital 
Clinical Site Preceptor 
-Dr. Christine Kurtz 
Valparaiso University  
Project Advisor 
-Dr. Nola Schmidt 
Valparaiso University 
Project Advisor 
  
 
  
 
Patients must know their email and password that is 
associated with the app. store on their phones. Ensure phone 
updates are completed prior to initial visit. Ensure email and 
password is known for app. verification purposes. 
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Appendix B 
Demographic Collection Form 
CODE 
 
PRE-
HbA1C 
AGE DOB 
 
 
SEX 
1= 
FEMALE 
2= 
MALE 
RACE 
1= 
WHITE 
2= 
BLACK 
3= 
HISPANIC 
4= 
OTHER 
MEDICATION 
1= ORALS 
2= INSULIN 
3= ORALS AND 
INSULIN 
4= ORALS AND 
NON-INSULIN 
INJECTIBLE 
5= NON-
INSULIN 
INJECTIBLE 
6= ORALS, 
INSULIN, AND 
NON-INSULIN 
INJECTIBLE 
YEARS 
DX 
WITH 
T2DM  
 
POST-
HbA1C 
001 10.0 52 7/10/67 2 1 2 3 8.9 
002 11.0 47 2/20/72 1 1 3 10 9.0 
003 9.7 58 4/7/61 1 1 1 15 7.4 
004 11.5 65 2/10/54 1 1 1 15 7.5 
005 8.9 57 12/14/61 1 1 6 15 7.5 
006 10.9 51 12/27/67 1 1 1 0.5 8.7 
007 9.2 54 7/24/65 2 1 1 15 7.7 
008* 0 0 0 0 0 0 0 0 
009 9.4 45 6/2/45 1 1 2 15 6.7 
110 10.0 43 7/14/76 1 1 3 15 8.3 
120 8.9 47 1/27/72 1 1 3 22 6.7 
130** 10.6 49 5/21/70 1 1 1 11 0 
140** 8.4 36 1/2/83 2 1 2 10 0 
150** 12.4 42 8/5/76 2 1 1 7 0 
160* 0 0 0 0 0 0 0 0 
170 8.9 45 2/25/74 2 1 1 10 7.2 
180** 11.0 45 12/14/73 1 1 2 8 0 
190* 0 0 0 0 0 0 0 0 
200 9.9 62 7/27/57 1 1 4 18 8.9 
210 9.6 43 5/30/76 1 1 2 3 9.7 
220 11.8 55 3/24/64 2 1 2 21 10.4 
230 9.8 44 1/27/75 1 1 3 10 8.1 
240 8.4 48 11/9/71 1 1 1 0.5 6.8 
250 10.3 71 9/1/48 1 1 3 31 8.5 
260 9.0 52 6/25/67 2 1 3 10 9.7 
* Participant did not start the program as intended 
** Participants did not finish the program 
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Appendix C 
Participant Information Sheets 
 
 
Living Sweet: 
    An Adult Type 2 Diabetes 
Mellitus Management 
Program 
Type 2 diabetes mellitus is one of the most chronic diseases, and the number of 
people who have it is getting higher.  
Staying on a treatment plan for diabetes is very hard, even when you know the 
bad health events that are because of high blood sugars and glycated 
hemoglobin (HbA1C). 
 
A HbA1C above 8.0 is diabetes that is not under control. This causes diabetic 
problems such as heart attacks, strokes, bad sight, loss of limbs, pain to nerves 
in the feet, and bad kidneys. 
 
The use of a mobile smart phone application (APP) has shown to lower blood 
sugars, increase workouts, help with medication plans, and lower HbA1C.  
 
Living Sweet is a program at Pulaski Memorial Hospital Clinics and was made 
because of research results that showed that APPs lower HbA1Cs and help to 
take medication, blood sugars, and doing workouts. 
 
When you join the 8-week program you will get hands-on and written details 
for downloading the free application to your smart phone, using the APP, 
setting reminders that are just about you and your goals, and uploading your 
information for your health care provider to review at a time that is easy for 
you. The project leader will come to you for this training. 
 
In general, the program will use an APP that is user-friendly, time-friendly, and 
can be used with an Android or iPhone. There is no cost to me.   
 
Please ask your provider if they think you could be in this program. You must 
be 18 years or older, have type 2 diabetes, have a HbA1C of more than 8.0, and 
have a smart phone. Pregnant women are not able to be in this program. 
 
 
 
 
 
  
 
 
Chantel Anderson  
MSN, FNP-BC 
Program Leader 
 
 
 
 
 
219-863-9298 
 
 
 
 
canderson@pmhnet.com 
  
 
 
-Melissa Jones 
Pulaski Memorial 
Hospital 
Clinical Site Preceptor 
-Dr. Christine Kurtz 
Valparaiso University  
Project Advisor 
-Dr. Nola Schmidt 
Valparaiso University 
Project Advisor 
 
Mobile Application to Improve Glycemic Outcome                                                             100 
 
 
   I agree to join the 8-week Living Sweet Program, and I know that I can leave at 
any time for any reason without a problem.   
 
I know that this program will not change regular health care services that I 
receive from my current provider. 
 
I know that I can join for free, and it will stay free even if I stop the program 
before the end of the 8-weeks.  
 
I know that my info will remain private and the HIPPA rules will be used with 
all services that I get. My name will always be kept secret by using a 
number code for the information about to me.  
 
I agree to let the project leader get the diabetic APP data that I offer or upload 
during the 8-week program.    
 
I understand that this program is meant to help change the way I 
take care of my daily diabetes by blood sugar checking, taking 
medication, and physical workouts. 
 
I understand using this phone APP is to lower a high HbA1C 
results.  
 
I understand that the data gathered from this program will be 
talked about at Valparaiso University and possibly other places. 
This is important to help other people care for their diabetes.  
 
I will keep in touch with the project leader during the 8-week 
program, and when I have questions about the APP or about the 
program. 
 
I agree to work with the project leader to select personal goals I 
want to reach by using the APP. These goals will be about taking 
medication, working out, and blood sugar testing that will help 
lower HbA1C levels.  
 
 
 
 
 
 
 
 
 
 
 
** KEEP FILLING OUT THE REST OF THE FORM 2 
PAGES** 
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NAME: 
__________________________________________________ 
 
 
DATE OF BIRTH:  _________________AGE: 
_________________ 
 
 
SEX: __________________________________________________________ 
 
 
EMAIL:____________________________________________________ 
 
 
PROVIDER EMAIL:____________________________________________ 
 
 
RACE:  _______________________________________________________ 
 
 
HOW MANY YEARS HAVE YOU KNOWN YOU HAD DIABETES? 
 
_______________________________________________________________ 
 
 
HOW OFTEN DO YOU EXERCISE? _____________________________ 
 
 
 
MEDICATIONS: 
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Appendix D 
Self-Care Inventory-Revised 
 
Self-Care Inventory-Revised Version (SCI-R) This survey measures what you actually do , not what you 
are advised to do.  How have you followed your diabetes treatment plan in the past 1-2 months?                                             
 NEVER RARELY SOMETIMES USUALLY ALWAYS  
1 Check blood 
glucose with 
monitor 
1 2 3 4 5  
2 Record blood 
glucose results 
1 2 3 4 5  
3 If type 1: 
check ketones 
when glucose 
level is high 
1 2 3 4 5 Have Type 2 
diabetes 
4 Take the 
correct dose of 
diabetes pills 
or insulin 
1 2 3 4 5 Not taking 
diabetes pills 
or insulin 
5 Take 
diabetes pills 
or insulin at 
the right time 
1 2 3 4 5 Not taking 
diabetes pills 
or insulin 
6 Eat the 
correct food 
portions 
1 2 3 4 5  
7 Eat 
meal/snacks on 
time 
1 2 3 4 5  
8 Keep food 
records 
1 2 3 4 5  
9 Read food 
labels 
1 2 3 4 5  
10 Treat low 
blood glucose 
with just the 
recommended 
amount of 
carbohydrate 
1 2 3 4 5  
11 Carry quick 
acting sugar to 
treat low blood 
glucose 
1 2 3 4 5 Never had low 
blood glucose 
12 Come in for 
clinic 
appointments 
1 2 3 4 5  
13 Wear a 
Medic Alert ID 
1 2 3 4 5  
14 Exercise 1 2 3 4 5  
15 If on 
insulin: Adjust 
insulin dosage 
based on 
glucose values, 
food, and 
exercise 
1 2 3 4 5 Not on insulin 
@Copyright:  Annette M. La Greca, University of Miami 
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Appendix E 
Check Point Tracking Form 
PC/ 
DOB 
IA1C SD ED WK 
1 
WK 
2 
WK 
3 
WK 
4 
WK 5 WK 6 WK 7 WK 
8 
EA1C WC 
001 
 
10.0 9/6 11/2 9/14 9/21 9/28 10/5 10/12 10/19 10/26 11/2 11/2 
8.9 
8 
002 
 
11.0 9/12 11/8 9/20 9/27 10/5 10/12 10/19 10/26 11/1 11/8 11/11 
9.0 
8 
003 
 
9.7 10/6 12/2 10/14 10/21 10/28 11/4 11/11 11/18 11/25 12/2 12/2 
office 
3 
004 
 
11.5 9/26 11/22 10/4 10/11 10/18 10/25 11/1 11/8 11/15 11/22 11/22 
home 
8 
005 
 
8.9 9/28 11/24 10/6 10/13 10/20 10/27 11/3 11/10 11/17 11/24 11/24 
7.5 
8 
006 12.3/ 9/13 11/9 9/21 9/28 10/6 10/13 10/20 10/27 11/2 11/9 11/11 
8.7 
8 
007 
 
8.9/ 9/17 11/13 9/25 10/3 10/10 10/17 10/24 10/31 11/6 11/13 11/15 
7.7 
8 
008 
 
x x x x x x x x x x x x x 
009 
 
9.4 9/26 11/22 10/4 10/11 10/18 10/25 11/1 11/8 11/15 11/22 11/22 
home 
3 
110 
 
10.0 9/27 11/23 10/5 10/12 10/19 10/26 11/2 11/9 11/16 11/23 11/23 
home 
6 
120 
 
8.9 10/1 11/24 10/9 
 
10/16 10/23 10/30 11/6 
 
11/13 11/20 11/27 11/27 
home 
4 
130 
 
10.6 
 
10/8 12/4 10/16
x 
10/23
x 
10/30
x 
11/6 
x 
11/13
x 
11/20
x 
11/27
x 
12/4 
x 
12/4 
home 
x 
140 
 
8,4 10/16 12/12 10/24
x 
10/31
x 
11/7 
x 
11/14
x 
11/21
x 
11/28
x 
12/5 
x 
12/12
x 
12/12 
home 
x 
150 
 
12.4 10/1 11/27 10/9 
x 
10/16
x 
10/23
x 
10/30
x 
11/6 
x 
11/13
x 
11/20
x 
11/27
x 
11/27 
home 
x 
160 
 
x x x x x x x x x x x x x 
170 
 
8.9 10/1 11/27 10/9 10/16 10/23 10/30 11/6 11/13 11/20 11/27 11/27 
call 
4 
180 
 
11.0 10/1 11/27 10/9 
x 
10/16
x 
10/23
x 
10/30
x 
11/6 
x 
11/13
x 
 
11/20
x 
11/27
x 
11/27 
home 
x 
190 
 
x x x x x x x x x x x x x 
200 
 
9.9 10/11 12/7 10/19 10/26 11/2 11/9 11/16 11/23 11/30 12/7 12/7 
office 
5 
210 
 
9.6 10/10 12/5 10/17 10/24 10/31 11/7 11/14 11/21 11/28 12/5 12/5 
home 
6 
220 
 
11.8 10/8 12/4 10/16 10/23 10/30 11/6 11/13 11/20 11/27 12/4 12/4 
home 
0 
230 
 
9.8 10/8 12/4 10/16 10/23 10/30 11/6 11/13 11/20 11/27 12/4 12/4 
home 
3 
240 
 
8.4 11/7 1/9/2
0 
11/15 11/22 11/29 12/6 12/13 12/20 12/27 1/2/ 
20 
1/2/ 
20 
office 
8 
250 
 
10.3 11/25 1/15/
20 
11/27 12/4 12/11 12/18 12/24 1/2/2
0 
1/8/2
0 
1/15/
20 
1/15/2
0 
8 
260 
 
9.0 11/14 1/9 11/21 11/28 12/5 12/12 12/19 12/26 1/2/ 
20 
1/9/ 
20 
1/9/ 
20 
 
8 
CODES: 
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X= DID NOT START OR FINISH THE PROGRAM 
 PC= PARTICIPANT CODE.   DOB= DATE OF BIRTH. 
IA1C= INITIAL HBA1C, INITIAL SELF-CARE INVENTORY-REVISED TOOL, PATIENT-DRIVEN BEHAVIOR GOAL 
SETTING. 
SD= START DATE.    ED= END DATE. 
WK1= WEEK 1 CHECK POINT COMPLETED. 
WK2= WEEK 2 CHECK POINT COMPLETED. 
WK3= WEEK 3 CHECK POINT COMPLETED. 
WK4= WEEK 3 CHECK POINT COMPLETED. 
WK5= WEEK 3 CHECK POINT COMPLETED. 
WK6= WEEK 5 CHECK POINT COMPLETED. 
WK7= WEEK 7 CHECK POINT COMPLETED. 
EA1C= (WEEK 8 CHECK POINT COMPLETED) END OF PROGRAM, FINAL HBA1C, REPEAT SELF-CARE 
INVENTORY-REVISED TOOL, PARTICIPANT SATISFACTION SURVEY.  
WC= WEEKS COMPLETED: 1= 1 WEEK, 2= 2 WEEKS, 3 = 3 WEEKS, 4= 4 WEEKS, 5= 5 WEEKS, 6 = 6 WEEKS, 7= 7 
WEEKS, 8= 8 WEEKS. 
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Appendix F 
Tracking Calendar 
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Appendix G 
Patient Satisfaction Survey 
*PLACE 1 CHECK FOR EACH LINE* 
Please rate your experience with the use of the diabetes-specific mobile phone application 
MySugr® 
 STRONGLY 
AGREE =5 
AGREE           
= 4 
UNDECIDED  
= 3 
DISAGREE    
= 2 
STRONGLY 
DISAGREE=1 
I found the 
application 
easy to upload 
on my phone. 
     
I found the 
application 
easy to use.  
     
I found the 
application 
made it easy 
to upload my 
results to my 
provider. 
     
I found 
application 
helped me to 
track my blood 
sugar results. 
     
I found the 
application 
helped me to 
track my 
physical 
activity.  
     
I found the 
application 
helped me to 
track my 
medications. 
     
OVERALL, I 
found the 
application 
helped me to 
manage my 
diabetes. 
     
 
 
Mobile Application to Improve Glycemic Outcome                                                             107 
 
 
Appendix H 
Behavior Tracking form 
Living Sweet: A Multi-Functional Mobile-Phone Application Strategy for Adults with Uncontrolled 
Type 2 Diabetes Mellitus 
 
CODE WEEK # GLUCOSE 
1=MET 
2= NOT MET 
PHYSICAL 
ACTIVITY 
1=MET 
2=NOT MET 
MEDICATION 
ADHERENCE 
1=MET 
2 = NOT MET 
INITIAL A1C WEEK 1    
Glucose/Goal:  WEEK 2    
 WEEK 3    
Activity/Goal: WEEK 4    
 WEEK 5    
Medication/Goal: WEEK 6    
 WEEK 7    
FINAL A1C 
 
WEEKS:  
WEEK 8    
 
 
CODE WEEK # GLUCOSE 
1=MET 
2= NOT MET 
PHYSICAL 
ACTIVITY 
1=MET 
2=NOT MET 
MEDICATION 
ADHERENCE 
1=MET 
2 = NOT MET 
INITIAL A1C WEEK 1    
Glucose/Goal:  WEEK 2    
 WEEK 3    
Activity/Goal: WEEK 4    
 WEEK 5    
Medication/Goal: WEEK 6    
 WEEK 7    
FINAL A1C 
 
WEEKS: 
WEEK 8    
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Appendix I 
Provider Information Sheet 
 
Living Sweet: 
An Adult Type 2 DM 
Management Program 
PROVIDER INFORMATION: 
PURPOSE: This is an evidence driven project aimed at 
reducing glycated hemoglobin, while fostering self-care 
perception and self-care behaviors such as medication 
adherence, blood glucose monitoring, and physical activity 
engagement through the use of a diabetes-specific mobile 
smart phone application. 
INCLUSION CRITERIA: Participants must be 18 years or 
older, have type II diabetes, have the most recent HbA1C of 
greater than 8.0, and have access to a mobile smart phone. 
Pregnant women are not able to be in this program. 
GENERAL INFORMATION FOR PARTICIPANTS: 
PROGRAM OVERVIEW: 
• Free diabetes-specific mobile application to be down 
loaded to the participant’s mobile smart phone. 
(Android and iPhone compatible) 
• In person, hands-on and written instructions will be 
provided by the project leader or designee. Access to 
the project leader will be available 7 days a week for 
trouble shooting and questions. 
• Patient-centered, individualized reminders and goals 
will be set for each participant at the initial meeting and 
can be adjusted throughout the pilot program to meet 
individual needs of each participant. 
• Each participant will be encouraged to use the 
application for a minimum of 8 weeks, and upload and 
send results to the project leader or designee. After 8 
weeks an HbA1C will be recorded. They may choose to 
stop the program at any time for any reason. 
PRODUCT: 
• A diabetes-specific mobile application: Mysugr® will be 
used for this pilot program to encourage self-
management behaviors that ultimately lead to improved 
HbA1C results. 
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Appendix J 
EMR Referral Page 
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Appendix  K 
Participant Privacy Log 
Living Sweet: A Multi-Functional Mobile-Phone Application Strategy for Adults with Uncontrolled 
Type 2 Diabetes Mellitus 
 
NAME CODE DATE OF BIRTH PHONE NUMBER 
 001   
 002   
 003   
 004   
 005   
 006   
 007   
 008   
 009   
 110   
 120   
 130   
 140   
 150   
 160   
 170   
 180   
 190   
 200   
 210   
 220   
 230   
 240   
 250   
 260   
 
 
 
 
 
 
